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Abstract 
Phosphopantetheine is an essential biomolecule required for life. The enzyme 
phosphopantothenoylcysteine synthetase (PPCS) incorporates the reactive thiol moiety in 
the Coenzyme A (CoA) biosynthetic pathway. Two types of PPCS exist in bacteria: 
bifunctional fusion protein Type 1 and monofunctional Type 3. Previously developed 
cytidylate mimics were determined to have stronger binding affinity for Type 3 
Streptococcus pneumoniae PPCS compared to Type 1. To explore the structure activity 
relationship of Type 3 PPCS, completely conserved residues of bacterial PPCS were 
probed via saturation mutagenesis in a developed knockout system. Mutagenesis revealed 
that conserved S. pneumoniae PPCS residues K123 and D93 were stringent, as only 
K123N/R/M and D93E/N were viable mutations. D93 was determined to be responsible 
for the association of divalent cations and CTP to the active site, as D93E and D93N 
exhibited a 1.5-2.7 fold (151-267 μM apparent Km) less affinity for CTP and D93N 
resulted in a 2-fold drop in MgCl2 affinity. K123 was identified as catalytically 
significant to the first half CTP utilizing reaction as the K123M and K123R mutations 
had 1.4-8.8 fold (142-872 μM apparent Km) loss in the binding affinity for CTP. 
 Additionally, phosphopantetheine is the essential prosthetic group of acyl carrier 
protein (ACP), utilized by gram negative specific acyltransferases (LpxA and LpxD) to 
construct lipopolysaccharide (LPS). Peptide RJPXD33 (TNLYMLPKWDIP) was 
discovered to bind and inhibit both LpxA and LpxD (binding constants of 22 μM and 6.5 
μM respectively), offering a probe for the development of a dual targeting small molecule 
x 
 
inhibitor. The molecular binding mechanism by which RJPXD33 interacts with LpxD 
was elucidated via fluorescence polarization based binding assays of truncated and 
alanine-mutated peptide. RJPXD33 P7 was identified to be important to binding LpxD as 
mutation of the residue to alanine resulted in a binding constant >50 μM, while similar 
tests in LpxA had a limited effect on binding (9.4 ± 0.6 μM). Residue K8 appeared 
inconsequential, as mutation to alanine had little effect on binding to LpxA or LpxD (5.1 
μM and 3.1 μM binding constants, respectively), but essential to inhibition. Photo-labile 
RJPXD33 probes were implemented for mapping LpxD-RJPXD33 protein-peptide 
interactions.   
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Chapter 1 
Introduction 
 
The Essential Biomolecule Phosphopantetheine 
Cofactors are non-protein components that are essential for the activity of a 
multitude of life sustaining enzymes. For metabolism to occur, functional groups must be 
transferred to and from metabolites, and all of these transfer reactions require a loosely 
bound cofactor to carry these functional groups between enzymatic reactions (1,2). 
Broadly, cofactors can be divided into two categories: inorganic cofactors and organic 
cofactors (3). Inorganic cofactors include metal ions (4), as well as metallo-organic 
complexes, such as the heme groups (5). Organic cofactors are small organic molecules 
that directly participate in the enzymatic reaction, and in some cases can be covalently 
bound as a prosthetic group (6). Several cofactors are derived from vitamins, partially 
reflecting the essential nature of vitamins, including nicotinamide adenine dinucleotide 
(7), tetrahydrofolic acid (8), and Coenzyme A (9).  
Coenzyme A (CoA) is an organic cofactor utilized in 4% of all enzymatic 
reactions (10). It consists of the essential biomolecule, phosphopantetheine, linked to an 
adenyl group (Figure 1.1), and has been discovered as an essential cofactor in all forms 
of life thus far (10). Fulfilling a multitude of roles, CoA serves as an acyl carrying 
cofactor in many organisms and is a required cofactor for the oxidation in lipogenesis and 
pyruvate oxidation in the citric acid cycle, and in certain bacteria is believed to create and 
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maintain the reductive environment (9,11). Coenzyme A also serves as the biological 
source of phosphopantetheine for acyl carrier protein (ACP), peptidyl carrier protein 
(PCP) and aryl carrier protein (ArCP) (9,12,13). In gram-negative bacteria, the formation 
of lipopolysaccharide (LPS), the outer layer of the outer membrane requires 
phosphopantetheine as a prosthetic group of acyl-ACP, required for the catalytic 
acylation of UDP-GlcNAc by LpxA and LpxD (14-16). Low levels of intracellular CoA 
has been shown to cause slowed growth in Escherichia coli (17). Genetic and chemical 
knockouts of the CoA biosynthetic pathway have been shown to be lethal, further 
reflecting the essential nature of the cofactor (18-20).  
Phosphopantetheine is of particular interest within CoA, as it serves as the active 
prosthetic group (12). Phosphopantetheine is derived from pantothenate, containing a 
cystamine/β-alanine dipeptide linked to a phosphorylated pantoyl group (Figure 1.1). 
Most organisms obtain phosphopantetheine via de novo synthesis along the Coenzyme A 
biosynthetic pathway, although not all organisms have the complete pathway (21). 
Obligate parasites such as those in the Chlamydia family appear to have no CoA 
biosynthetic pathway yet rely on CoA and ACP for LPS and glycerol phosphate 
biosynthesis for growth (22). It has been proposed that organisms without CoA synthetic 
pathways are able to transport some phosphopantetheine containing biomolecules and 
modify them to suit need. Additionally, some bacteria, such as Escherichia coli, are able 
to utilize a salvage pathway wherein the precursor pantetheine can be imported from the 
environment via a ‘pantetheine shunt’ and used to generate phosphopantetheine (23). 
Without the reactive thiol moiety phosphopantetheine introduces, CoA is rendered 
ineffectual. Thusly, analogs of pantetheine missing the thiol residue have been developed 
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to utilize the ‘pantetheine shunt’ to become potent antimetabolites of CoA (24-28). The 
essential nature of the phosphopantetheine thiol in CoA allows for the development of 
potential antimicrobial agents (29). 
 The essential nature of phosphopantetheine as well as the divergence in homology 
between microbial and eukaryotic enzymes that construct this pathway (30), make 
targeting its synthesis in microbes a novel target for the development of small molecule 
antimicrobials. Additionally, the gram-negative specific utilization of 
phosphopantetheine in the acyl transfer reactions of the biosynthesis of LPS offer another 
unique target for the development of small molecule antibiotics. The work herein focuses 
on elucidating key target-inhibitor molecular binding mechanisms with enzymes that 
either produce (phosphopantothenoylcysteine synthetase) or directly interact with (early 
LPS acyltransferases) the essential biomolecule phosphopantetheine. The goal in doing 
so is to provide valuable insight for the rational design of potent small molecule 
antibiotics. 
 
Coenzyme A Biosynthesis as a Target for Antimicrobial Development 
 The de novo synthesis of CoA occurs in nearly all organisms in five highly 
conserved steps (Figure 1.2) (31). Pantothenate (Vitamin B5) is first phosphorylated by 
pantothenate kinase (PanK; EC 2.7.1.33; coaA) to 4’-phosphopantothenate. In a two-step 
reaction, phosphopantothenoylcysteine synthetase (PPCS; EC 6.3.2.5; coaB) uses a NTP 
to form an activated cytidylate intermediate, followed by condensation with cysteine to 
form phosphopantothenoylcysteine. Following a rare cysteine decarboxylation by 
phosphopantothenoylcysteine decarboxylase (PPCDC; EC 4.1.1.36; coaC), 
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phosphopantetheine is formed (32,33). Phosphopantetheine adenyltransferase (PPAT; EC 
2.7.7.3; coaD) adenylates phosphopantetheine at the 4’-phosphate to generate dephospho-
coenzyme A (deCoA). In the final step, dephospho-CoA kinase (DPCK; EC 2.7.1.24; 
coaE) phosphorylates the 3’ hydroxyl of the ribose sugar, forming CoA. 
 Although enzymes in CoA biosynthesis are highly conserved, there is a great deal 
of diversity among the enzymes between different species (30). Amino acid sequence 
similarities between human and bacterial CoA biosynthetic pathways are visualized in 
Figure 1.3. Overall, there is very low sequence similarity between human and bacterial 
CoA biosynthetic enzymes. Human PPCS shares less than 20% sequence similarity with 
all of the species listed, except of Enterococci faecalis and Streptococcus pneumoniae, of 
which the human PPCS shares a 20-30% sequence similarity. Such low sequence 
similarity is a good indication that selective inhibition of bacterial Coenzyme A 
producing enzymes may make good therapeutic targets. Additionally, E. coli PPCS 
shares at least a 20% sequence similarity with other bacterial PPCS, and in several cases 
a much higher sequence similarity. This suggests that broad spectrum chemotherapeutics 
can be developed that target bacterial PPCS. 
 Pantothenate kinase (PanK; EC 2.7.1.33; coaA) is expressed in several varieties. 
Type 1 PanK is expressed in some bacteria, including Escherichia coli, and has been 
determined to be a vital component in the salvage of pantetheine. This PanK is able to 
phosphorylate extracellular pantetheine to bypass the PPCS/PPCDC enzymatic reactions 
and produce 4’-phosphopantetheine (24). The pantothenate analog N-
pentylpantothenamide (N5-Pan) has been determined to be a substrate of Type 1 PanK, 
but will produce inactive ethyldethia-CoA (27,34). N-heptylpantothenamide (N7-Pan) as 
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a substrate will produce similar results (25). Likewise, Type 2 PanK, expressed in 
Staphalyococcus aureus and other gram positive bacteria, is able to utilize N5-Pan and 
N7-Pan, which act as more potent antimicrobials as a result of inactive CoA formation 
(35). Type 2 PanK is not feedback inhibited by CoA (11), which is likely why N5 and 
N7-Pan are much more potent in S. aureus than in E. coli. A Type 3 PanK, discovered in 
Bacillus subtilis, is present in a majority of bacteria and is expressed by coaX (23). Type 
3 PanK has been found not to phosphorylate N5-Pan and N7-Pan, due in part to its much 
smaller active site (36). Type 3 PanK is unable to phosphorlyate panthetheine, consistent 
with the enzyme’s inability to utilize akyl-pantothenamides as alternative substates to 
pantothenate (37). Additionally, Type 3 PanK is not feedback inhibited by CoA, and thus 
it remains uncertain if it plays any role in CoA regulation (38,39). 
Phosphopantothenoylcysteine synthetase (PPCS; EC 6.3.2.5; coaB) is a critical 
enzyme in the CoA biosynthetic pathway, as it is responsible for the incorporation of the 
reactive thiol. As with PanK, PPCS is expressed in three types. Most bacteria express 
Type 1 PPCS, which is the bifunctional PPCS/PPCDC fusion protein (40,41). In the first 
half reaction, Type 1 PPCS exclusively utilizes CTP. Higher eukaryotes, including 
humans, express a monofunctional Type 2 PPCS and a separate monofunctional PPCDC 
(10). Type 2 PPCS has a much larger nucleotide binding pocket and will utilize ATP or 
CTP for the first half reaction, however the higher intracellular concentration of ATP 
make it the more physiologically relevant substrate. S. pneumoniae and E. faecalis 
express Type 3 monofunctional PPCS that utilizes CTP in a manner similar to that of 
Type 1 PPCS (42). Differences in the activity of the PPCS enzyme between human and 
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bacterial systems and the requisite nature of the enzyme make it a feasible target for the 
development of small molecule antimicrobial agents.  
In vitro inhibitors of PPCS have been constructed and characterized by our group 
(Figure 1.4). Cytidylate intermediate mimics of PPCS have been synthesized and 
characterized as slow on-set, tight-binding inhibitors (43,44). Phosphopantothenate 
analogs have also been constructed, with phosphopantothenthiol determined to be a 
phosphopantothenate-competitive inhibitor of E. coli PPCS with a low µM Ki. 
Additionally, S. pneumoniae PPCS has previously been screened by our group against 
41,000 compounds at the University of Michigan Center for Chemical Genomics. The 
screening process provided isoxazole-containing compounds that offer low µM inhibition 
of the monofunctional PPCS in vitro but have limited in vivo efficacy (45).  
Previous structural studies have revealed that both bacterial and eukaryotic PPCS 
are active dimers (40,46). Crystal structure of the inactivated E. coli Type 1 
PPCS(N210D) and human Type 2 PPCS have revealed that a lysine (K123 in E. coli) 
from one monomer completes the active site at the other monomer’s asparagine (N210 in 
E. coli). A of native E. coli Type 1 PPCS was obtained upon co-crystallization with the 
cytidylate intermediate JDP03 (44). This structure revealed that the internal phosphate of 
the compound makes a salt bridge with E. coli Lys341 and binding contact with Lys289, 
a residue that was previously determined to be critical to the enzymatic catalysis of PPCS 
(47). This crystal structure gave a wealth of knowledge for improving inhibitors against 
bacterial Type 1 PPCS; however no structural studies had yet been performed on Type 3 
PPCS.  
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While not all methods of phosphopantetheine acquisition have been fully 
investigated, it is possible to target specific methods in certain organisms for the purpose 
of developing selective antimicrobials. Specifically, de novo synthesis of 
phosphopantetheine can be interrupted in bacteria by targeting PanK, PPCS and PPCDC. 
However, in order to produce compounds which are able to serve as antimicrobials, 
functional activity of these proteins need to be further investigated. With more 
knowledge gained, target-based design of potent, cell wall permeable inhibitors of CoA 
biosynthesis can be achieved. A goal of the research efforts described herein is to 
determine the residues responsible for the chemistry and unique recognition of substrates 
in monofunctional PPCS. Our hypothesis is that understanding the role of conserved 
residues between bacterial bifunctional and monofunctional PPCSs will allow aspects of 
the molecular basis of catalysis and inhibition to be determined. With a detailed 
understanding of monofunctional PPCS catalysis and inhibition it will be possible to 
rationally design more potent small molecules that can selectively inhibit bacterial PPCS 
to serve as molecular probes in the study of bacterial CoA biosynthesis, as well as 
antimicrobial leads. 
 
Acyl Carrier Protein 
 As briefly mentioned earlier, phosphopantetheine also has the essential role as a 
prosthetic group outside of Coenzyme A; as the active moiety of acyl carrier protein 
(ACP) (48). ACP is expressed in an inactive apo form, requiring holo-acyl carrier protein 
synthase to perform a post-translational attachment of phosphopantetheine to a conserved 
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serine residue, forming active holo-ACP (12). The phosphopantetheine prosthetic group 
offers chain flexibility and can form covalent bonds with intermediates (49). 
ACP is universal and essential to fatty acid synthesis (50). Most bacteria utilize 
Type II fatty acid synthesis, wherein each step in fatty acid synthesis is performed by a 
different enzyme, unlike the mammalian Type I fatty acid synthesis wherein one 
polyprotein performs all of the steps (51,52). Inhibiting the interactions of these fatty acid 
synthesis enzymes with ACP by the introduction of natural product and small molecules 
offers significant potential for the development of antimicrobials (53-55). Currently, the 
drug triclosan is able to inhibit bacterial fatty acid synthesis by forming a ternary 
complex with enoyl-ACP reductase, no longer allowing it to interact with ACP and 
participate in fatty acid synthesis (56). However, broad spectrum usage of triclosan offers 
bacterial resistance concerns (57), and there is still a lack of basic understanding of the 
diversity in regulation of lipid metabolism in bacteria (53). 
ACP also has specialized functions that are specific to bacteria (50). Of particular 
therapeutic interest are ACP’s interactions with the acyltransferases involved in the 
construction of the cell membrane of gram-negative bacteria (58). The essential nature of 
ACP makes selectively inhibiting its interactions an intriguing chemotherapeutic target. 
My research, in part, focuses on ACP’s interactions with the early acyl transferases in the 
Raetz Lipid A biosynthetic pathway of gram negative bacteria.  
 
Lipid A Biosynthesis as a Target for Antimicrobial Development 
Lipopolysaccharide (LPS) forms the asymmetrical outermost monolayer of the 
cell membrane of gram-negative bacteria (Figure 1.5) (59,60). Additionally, LPS serves 
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as a hydrophobic permeability barrier that protects gram negative bacteria from 
hydrophobic antibiotics (61,62). LPS is composed of three core components: lipid A, a 
core polysaccharide region, and the outermost repeating O-antigen polysaccharide (60). 
Lipid A is the essential oligosaccharide moiety of LPS, responsible for anchoring the 
moiety to form the outer monolayer of the outer cell wall membrane of Gram-negative 
bacteria (59,60,63). Lipid A is essential to growth in most Gram-negative bacteria (64,65) 
and modification to lipid A plays a role in protecting the bacteria from environmental 
stress (60). 
LPS is also known as endotoxin, and triggers the host-cell response required for 
bacterial clearance (59). During infection, released lipid A initiates the host-cell immune 
response via the TLR4-MD-2 complex (66-70). Overstimulation of this complex can 
occur and lead to septic shock and ultimately death (69,71,72). The requisite nature and 
toxicity of lipid A make its biosynthetic pathway an optimal target for antimicrobial 
chemotherapeutic discovery (54,58,65,73,74). 
 The biosynthesis of lipid A consists of nine consecutive enzymatic processes 
(Figure 1.6) (75). Acyltransferase LpxA performs the first step through a 
thermodynamically unfavorable reaction, utilizing an acyl carrier protein (ACP) to 
acylate UDP-N-acetylglucosamine (UDP-GlcNAc) at the 3-hydroxyl, producing UDP-3-
O-(R-3-hydroxymyristoyl)-N-acetylglucosamine (15,75). Subsequent deacylation of the 
N-acetyl moiety by LpxC provides the first committed step of lipid A biosynthesis and is 
a key regulatory step in the E. coli pathway (76-78). Acyltransferase LpxD utilizes ACP 
to catalyze the third reaction, acylating the free amine of the glucosamine ring (79). Six 
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more enzymatic reactions follow to catalyze the formation of hexa-acylated Kdo2-lipid A 
moiety of LPS (59). 
 Temperature sensitive mutants of the early step of the lipid A biosynthetic 
pathway have demonstrated that lipid A is required for the viability of the microbe and 
that the activity of these early steps are required for the maintenance and growth of the 
microbe (77,79,80). Overexpression of LpxA and LpxD inhibitory peptides has also 
demonstrated toxicity in E. coli (81,82). Synthetic molecules screened against the lipid A 
biosynthetic pathway yielded small molecule inhibitors of LpxC that exhibited an MIC of 
1 µg/ml against E. coli (73). These compounds were expanded via crystallographic and 
structure-activity relationship studies to create a potent, broad spectrum inhibitor of LpxC 
(58,83,84). Development of such inhibitory compounds chemically validates the early 
steps of the Raetz pathway as antimicrobial targets. 
LPS between different microbes can look very different, with varying external 
repeating oligonucleotides and varying numbers of Kdo modifications to the lipid A core 
(59). However, regardless of the diversity of LPS as a whole, the lipid A anchor moiety is 
relatively conserve. Nearly all lipid A contains the same glucosamine core, although 
Leptospira interrogans will convert the 3’-hydoxyl of UDP-GlcNAc to an amine (85,86). 
Most of the diversity of lipid A between microbes is a result of the acyl chain lengths that 
the acyltransferases (LpxA and LpxD) utilize as a substrate (87-90).  
 LpxA is expressed as a trimeric enzyme, with an active site located at a catalytic 
histidine on each of the monomers of the trimer (91,92). This histidine deprotonates the 
3’ hydroxyl of UDP-GlcNAc, which allows for the nucleophilic attack into the 
phospopantotheine-acyl thioester of the acyl-ACP substrate (89,93). Crystal structures 
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have demonstrated that acyl chains are able to bind the hydrophobic pocket located at the 
intersection of monomeric subunits (85,94). These hydrophobic pockets contain a 
histidine residue that serves as the ‘hydrocarbon ruler,’ responsible for the selectivity of 
acyl chains incorporated into the lipid A core by LpxA (95). 
In addition to sharing similar enzymatic activity, LpxD also shares a high 
sequence homology with LpxA (27.2%) (96). Not surprisingly, crystal structures of LpxD 
demonstrates that it share a similar structure to LpxA, with a left-handed β-helical motif 
(97). LpxD also contains an α-helical UDP-binding domain and C-terminal α-helical 
extension region. Structural differences in the C-terminus of the LβH domain is 
responsible for the differences in acyl-chain length selectivity between E. coli and C. 
trachomatis LpxD (97).  
Peptides have provided an invaluable tool in the study of the Raetz pathway acyl-
transferases. Phage display was utilized by Benson et. al. to identify peptide P920, a 12-
mer inhibitory peptide of LpxA (82). As a prelude to the development of rationally 
designed small molecule inhibitors of LpxD, inhibitory peptide RJPXD33 was identified 
via phage display by Jenkins et. al. (81). A co-crystal structure of RJPXD33 with E. coli 
LpxA demonstrated that the six N-terminal residues of the peptide bind the hydrophobic 
pocket of the enzyme, within 2.8 Å of the His191 hydrocarbon ruler (14). This site 
normally is occupied by the substrate acyl-chain of acyl-ACP, suggesting that RJPXD33 
binds LpxA and inhibits the enzyme by preventing its association with acyl-ACP. 
Overlaying the LpxA-RJPXD33 crystal structure with the crystal structure of the LpxD-
acyl-ACP complex reveals that peptide likely fills the same space as the 
phosphopantetheine arm of acyl-ACP (14). However, peptides serve as poor 
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antimicrobials due to proteolytic cleavage. In order to design potent compounds, 
extensive characterization of RJPXD33 was required. 
 
Thesis Outline 
Antibacterial research has afforded mankind exceptional improvements in the 
quality of life since the 1930s (98). However, bacterial resistance to currently used 
therapeutics is increasing at an alarming rate, and the rate that new antibiotics are 
introduced to the market has slowed dramatically since the 1970s (99,100). As such, there 
is a call for the design of novel antibacterial chemotherapeutics to combat the rise of 
resistance. The biomolecule phosphopantetheine is one intriguing target for the 
development of novel antimicrobial agents, as it is essential across life but there are 
divergences in its production and utilization between human and bacteria 
(35,53,54,101,102).  
Small molecule probes serve as vital chemical biological tools for the 
development of antibiotics. They afford a strong platform for evaluating the utility of a 
chemical space to serve as an inhibitor of target enzymes and allow determination of key 
molecular binding activity in the inhibitor-enzyme complex. While they themselves 
cannot directly be utilized as antimicrobial agents, either due to an inability to reach the 
target within the in vivo system or due to chemical instability, the knowledge they afford 
for the rational development of small molecule antimicrobials is indispensible. The work 
presented herein both utilizes and characterizes molecular probes to inhibit the 
production and utilization of phosphopantetheine in bacterial systems, providing key 
insight to the molecular binding mechanisms of the probes. 
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The overall goal of the research efforts described herein is to target the production 
and utilization of phosphopantetheine in bacterial systems as a target of antimicrobial 
agents. This research was directed along two pathways: 1) PPCS incorporation of the 
moiety into CoA, and 2) utilization of the moiety by LpxA and LpxD in the formation of 
lipid A. Our hypothesis is that understanding the role of conserved residues between 
bacterial bifunctional and monofunctional PPCSs will allow aspects of the molecular 
basis of catalysis and inhibition to be determined. Among these aspects are 
phosphopantothenate binding, cysteine selectivity, and inhibitor binding. Additionally, 
the further characterization and utilization of peptide RJPXD33 will provide essential 
insight to the molecular binding mechanisms for both LpxA and LpxD, as well as provide 
a scaffold for the development of small molecule antimicrobial acyltransferases 
inhibitors. 
In Chapter 2, Type 3 S. pneumoniae PPCS is evaluated in depth in order to 
determine the key residues for activity and substrate recognition. A multiple sequence 
alignment of all bacterial PPCS (both Type 1 and Type 3) was performed to highlight 
completely conserved residues. Mutagenenic studies were performed in E. coli Type 1 
PPCS and S. pneumoniae Type 3 PPCS to determine if they shared catalytic roles across 
bacterial PPCS.A double knockout E. coli based expression strain was developed in order 
to quickly verify the PPCS mutants in vivo, and follow up in vitro characterization was 
performed via a continuous pyrophosphatase-coupled assay. These studies provided a 
chemical-biological basis for interactions of previously discovered small molecule 
inhibitors of PPCS. 
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In Chapter 3, acyltransferase binding studies utilizing various derivatives of 
RJPXD33 were undertaken in order to investigate key residues for binding of RJPXD33 
to LpxD and discover how the peptide’s structure dictates its dual inhibitor nature. 
Specifically, alanine scanning was performed on RJPXD33 to determine the contribution 
of each residue to the overall binding of LpxA and LpxD, and the residues important to 
the binding of both proteins. Additionally, residues responsible for the unique recognition 
of LpxA or LpxD were identified. Truncations of the RJPXD33 peptide were also made 
at the C-terminus in order to determine the minimum sequence necessary to inhibit LpxD. 
Additionally, peptide photo-affinity probes were crosslinked to LpxD in attempts to 
validate binding model of RJPXD33-LpxD with high resolution mass spectrometry.  
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Figure 1.1: Structures of essential biomolecules pantothenate, phosphopantetheine, coenzyme A, 
and acyl carrier protein. 
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Figure 1.2: Biosynthetic pathway of coenzyme A. The five constitutively conserved enzymes are 
highlighted in blue. Essential biomolecule phosphopantetheine is in red. 
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Figure 1.3: Sequence similarity of CoA biosynthetic enzymes among several species. The left 
chart has percent identity relative to E. coli enzymes, while the right chart has percent identity 
relative to human enzymes. 
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Figure 1.4: Selected CoA biosynthetic pathway inhibitors. Phosphopantethiol is a 
phosphopantothenate mimic (44). JDP03 is a PPCS cytidylate intermediate mimic (44). JY1 is 
SPB03328, a high throughput screen hit that inhibits PPCS (45). 
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Figure 1.5: The outer membrane of gram-negative bacteria. The lipid A scaffold of Escherichia 
coli is shown in the insert. 
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Figure 1.6: Biosynthesis of lipoplysaccharide. 
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Chapter 2 
Activity of the Conserved Residues of Streptococcus pneumoniae 
Phosphopantothenoylcysteine Synthetase
 
Background  
 Phosphopantetheine is an essential biomolecule that is incorporated as the reactive 
moiety into several cofactors required in life sustaining processes, including Coenzyme A 
and the prosthetic group on acyl carrier protein (1-3). Phosphopantothenoylcysteine 
synthetase (PPCS; EC 6.3.2.5; coaB) incorporates the reactive thiol of 4’-
phosphopantetheine in a two step reaction, creating a nucleotide activated intermediate 
followed by a cysteine condensation (Figure 2.1). Following cysteine decarboxylation by 
phosphopantothenoylcysteine decarboxylase (PPCDC; EC 4.1.1.36; coaC), 4’-
phosphopantetheine is produced. PPCS is found in nature is three types. Most bacteria 
express Type 1 PPCS as a bifunctional PPCS-PPCDC which exclusively utilizes CTP in 
the activation step. Higher eukaryotes, including humans, express a monofunctional Type 
2 PPCS with a much larger nucleotide binding pocket, allowing for ATP to be utilized as 
well as CTP in the activation step. Streptococcus pneumoniae and Enterococcus faecalis 
express Type 3 monofunctional PPCS that utilizes CTP in a manner similar to that of 
Type 1 PPCS. The essential nature of phosphopantetheine and different types of PPCS 
within the Coenzyme A pathway between humans and bacteria make the pathway an 
intriguing target for antimicrobial development (4,5). 
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Mutagenesis studies of E. coli Type 1 PPCS revealed that point mutations N210D 
and K289Q led to a complete loss of phosphopantothenoylcysteine synthesis (6). HPLC-
based assays of the N210D mutant revealed that the protein utilized all available 
phosphopantothenate and produce cytidylate intermediate. Thus, Asp210 was determined 
to mediate the second half cysteine condensation, as mutation of this residue prevents the 
formation of phosphopantothenoylcysteine (7). From the HPLC-based assay, 
PPCS(K289Q) appeared to have no activity, as no detectable products were present. This 
would indicate that Lys289 is key to the first step substrate activation. Crystal structures 
of E. coli PPCS(N210D) with substrates revealed that Lys289 contacts the γ-phosphate 
oxygen atoms of CTP (8). 
In vitro inhibitors of PPCS have been constructed and characterized by our group. 
Cytidylate intermediate mimics of PPCS have been synthesized and characterized as slow 
on-set, tight-binding inhibitors (9). Phosphopantothenate analogs have also been 
constructed, with phosphopantothenthiol determined to be a phosphopantothenate-
competitive inhibitor of E. coli PPCS with a low µM Ki (10). Additionally, S. 
pneumoniae PPCS has previously been screened by our group against 41,000 compounds 
at the University of Michigan Center for Chemical Genomics. The screening process 
provided isoxazole-containing compounds that offer low µM inhibition of the 
monofunctional PPCS in vitro but have limited in vivo efficacy (11). To safely and 
rapidly evaluate Type 3 PPCS in vivo, the knockout strain E. coli 
MG1655::ΔpanC,ΔcoaBC::KanR was developed. By complementation of the knockout 
via a transformed low copy number plasmid carrying coaB and coaC genes, S. 
pneumoniae and E. faecalis PPCS proteins could be tested in vivo in a system with 
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controlled levels of cellular pantothenate. Herein, we discuss the development of the 
knockout strain MG1655::ΔpanC,ΔcoaBC::KanR, and the parameters of its growth when 
complemented with coaBC from other organisms. 
Currently, there is structural data for Type 1 E. coli PPCS, but no crystal structure 
of Type 3 S. pneumoniae PPCS. In order to utilize E. coli bifunctional PPCS 
structural/functional model for S. pneumoniae monofunctional PPCS highly conserved 
proposed active site residues were mapped for both monofunctional and bifunctional 
PPCS. Multiple sequence alignment of several monofunctional and bifunctional PPCS 
enzymes revealed several highly conserved residues. These residues also matched 
residues of high catalytic importance in the E. coli PPCS crystal structure. We propose 
that residues critical for monofunctional PPCS catalysis and specificity for CTP and 
cysteine are conserved between mono and bifunctional bacterial PPCS. Site-directed 
mutagenesis was first performed on specific catalytic residues of E. coli PPCS as well as 
at the corresponding sites of S. pneumoniae PPCS. Using the developed in vivo model 
system, these mutations were found to have matching phenotypes across E. coli and S. 
pneumoniae PPCS, suggesting a validation of our sequence alignment and that the active 
site of E. coli PPCS should share structural similarity. Saturation mutagenesis was then 
performed on S. pneumoniae PPCS at highly conserved residues in order to identify those 
residues responsible for the substrate recognition and activity of the protein. Through 
kinetic characterization of active mutants, we were able to elucidate residues vital to the 
activity of the protein, giving a chemical-biological basis for interactions of previously 
discovered small molecule inhibitors of PPCS. 
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Materials and Methods 
 Materials. All chemicals were used as purchased from Acros, Fisher, Fluka, 
Sigma-Aldrich, or Specialty Chemicals Ltd. and used without further purification unless 
otherwise noted. The Mono Q 5/50 GL, Source 15Q, Source 15S, and Superdex 200 resin 
and columns were purchased from GE Healthcare. Bio-Gel P2 resin was from Bio-Rad. 
Ni-NTA resin was from Qiagen. Additionally, Qiagen minispin kits were used for DNA 
purification and cleanup. Ammonium molybdate, ampicillin, L-arabinose, calcium 
pantothenate, chloramphenicol, L-cysteine, cytidine triphosphate, dithiothreitol, formic 
acid, concentrated hydrochloric acid, HEPES, imidazole, bacterial inorganic 
pyrophosphatase, isopropyl β-D-1-thiogalactopyranoside, kanamycin, magnesium 
chloride, magnesium sulfate, malachite green carbinol hydrochloride, methanol, D-
pantethine, pyrophosphate reagent, sodium chloride, sodium hydroxide, sodium 
pyrophosphate, and Tris HCl, and were purchased from Sigma-Aldrich. Luria-Bertani 
agar and broth were from Difco. DNA restriction and ligation enzymes and associated 
reagents were from New England Biolabs. BL21(DE3) Escherichia coli cells was 
purchased from Invitrogen and XL-1 Blue E. coli cells were from Stratagene. 384-well 
polystyrene nonbinding surface plates and 96-well half-area polystyrene nonbinding 
surface plates were purchased from Corning. Phosphopantetheine was synthesized as 
previously reported (12). DNA sequencing was performed by the University of Michigan 
DNA Sequencing Core facility. 
Generating double knockout E. coli ΔPanC,ΔcoaBC::KanR. Using P1 phage 
transduction and our lab’s previously generated E. coli MG1655 Δdfp (coaBC)::KanR and 
E. coli MG1655 ΔPanC::KanR mutant knockout strains, a double knockout E. coli 
30 
 
ΔPanC,ΔcoaBC::KanR strain, designated KH100, was developed (11,13). The 
temperature sensitive, ampicillin resistance pCP20 vector was transformed into the 
ΔPanC::KanR strain and induced to express a yeast FLP recombinase. Successful 
recombinants were selected for based on loss of kanamycin resistance and retention of 
ampicillin resistance selection of pCP20. The plasmid was then removed upon incubation 
at 42 °C overnight, with loss of vector selected for based on sensitivity to ampicillin. This 
afforded a ΔPanC E. coli strain with no kanamycin resitance that would become the 
“recipient strain.” Next, P1vir was transfected into the ΔcoaBC::KanR “donor strain” by 
adding 100 µl of 10
9
 pfu/ml P1vir to the donor strain growing logarithmically at 37 °C in 
5 mL of LB broth containing 0.2% glucose, 100 µM pantetheine and 5 mM CaCl2. The 
culture was incubated for 3 hours at 4 °C until lysis occurred, then the remaining bacteria 
were killed by the addition of a few drops of CHCl3 and cellular debris was removed by 
differential centrifugation. The supernatant containing P1 lysate was stored at 4 °C until 
use. The ΔPanC recipient strain was incubated overnight at 37 °C then 1.5 mL of culture 
was pelleted and resuspended in 10 mM CaCl2/5 mM MgSO4. The cells were then mixed 
with various amounts of the P1 lysate and incubated at room temperature for 30 minutes 
for phage absorption. The mixtures were then incubated for 1 hour at 37 °C in LB broth 
containing 200 mM sodium citrate, then plated onto LB plates containing 30 µg/ml 
kanamycin, 100 µM pantetheine and 5 mM sodium citrate. The plates were incubated 
overnight at 37 °C, and the plate with the least amount of P1 phage growth, single 
colonies were streaked onto kanamycin, pantetheine, sodium citrate plates and incubated 
overnight at 37 °C to remove infective phage. Surviving streaks were then screened for 
kanamycin resistance and loss of dfp (coaB-coaC) based on requirement of pantetheine 
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for growth. Selection screening for growth in the presence of pantetheine and kanamycin, 
but no growth on media not supplemented with panthetheine resulted in the appropriate 
phenotype of the ΔPanC,ΔcoaBC::KanR.  
Cloning of E. coli, E. faecalis, and S. pneumoniae coaBC. PCR protocols were 
carried out under standard conditions utilizing Pfu DNA Polymerase and DNA obtained 
from E. coli (MG1655), E. faecalis (ATCC 700802), and S. pneumoniae (TIGR4) and the 
primers listed in Table 2.1. The coaBC domains for E. coli and S. pneumoniae were 
amplified and cloned into pUMRJ100 using NdeI and HindIII restriction sites. E. faecalis 
coaBC was amplified and cloned into pUMRJ100 using NaeI and NdeI restriction sites. 
The pUMRJ100 plasmid was chosen because it is low copy, L-arabinose inducible, and 
contains Cam
R
 for additional chloramphenicol (Cam) resistance selection. Plasmids were 
transformed into E. coli XL-1 Blue cells for amplification. Genetic integrity of plasmids 
isolated from the cell lines was confirmed by sequencing at the University of Michigan 
Sequencing Core Facility. The vectors were then transformed into the double knockout 
cell line and plated onto LB media containing Cam and 1% L-arabinose to create the 
following strains: KH100/pUMRJ100/E. coli coaBC, KH100/pUMRJ100/E. faecalis, and 
KH100/pUMRJ100/S. pneumoniae coaBC. Colony growth on unsupplemented LB media 
proved the functional expression of coaB and coaC were able to recover the conditionally 
lethal coaBC knockout.  
Growth studies of complemented E. coli ΔPanC,ΔcoaBC::KanR. Plasmids 
containing coaBC on arabinose inducible pUMRJ100 were transformed into KH100 cells 
made chemically competent. Starter cultures (5 mL) of KH100/pUMRJ100/coaBC strains 
in LB (Lennox) containing 100 µM pantothenate were allowed to grow overnight at 37 
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ºC. The following day, cells were pelleted by centrifugation at 5000 x g, 4 ºC and 
resuspended in 5 mL fresh minimal salts (Difco) three times in order to remove residual 
pantothenate. Cell suspensions were then diluted to an OD600 of 0.01 in 150 ml fresh 
media that was a 1:1 mixture of minimal salts:pantothenate free media (Difco). These 
cultures we incubated with aeration at 37 °C for 24 hours. During incubation, 1 ml 
fractions were removed from each culture and evaluated for absorbance at λ = 600 nm.  
Cloning and expression of E. coli, E. faecalis, and S, pneumoniae PPCS. PCR 
protocols were carried out under standard conditions utilizing Pfu DNA Polymerase and 
DNA obtained from E. coli (MG1655), E. faecalis (ATCC 700802), and S. pneumoniae 
(TIGR4). The coaB gene for each bacteria was amplified and cloned into pET23a using 
NdeI and XhoI restriction sites and the primers listed in Table 2.2. Plasmids were 
transformed into E. coli XL-1 Blue cells for amplification. Genetic integrity of plasmids 
isolated from the cell lines was confirmed by sequencing at the University of Michigan 
Sequencing Core Facility.  For protein expression, vectors were transformed into BL21-
AI, to make the following strains: BL21-AI/pET23a::E.coli coaB, BL21-
AI/pET23a::E.faecalis coaB, BL21-AI/pET23a::S/ pneumoniae coaB-his6 and BL21-
AI/pET23a::S. pneumoniae coaB. The strains were used to inoculate 500 ml LB (Lennox) 
media containing 50 µg/ml ampicillin. The culture was incubated at 37 ºC with vigorous 
shaking (250 rpm) until the optical density at 600 nm reached ~0.6. The cultures were 
induced with 0.2% L-arabinose/1 mM IPTG and allowed to incubate at 37 ºC for 4 hours 
post-induction. Cultures were then cooled and harvested by centrifugation at 5,000 x g, 4 
ºC for 10 minutes. Cells were resuspended in 10 mL of 10% glycerol, 20 mM HEPES pH 
8.0 and stored at -80 ºC.  
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Purification of E. coli PPCS. Cell suspension strain BL21-AI/pET23a::E. coli 
coaB was thawed then disrupted by French press at 20,000 psi and the insoluble debris 
was removed by centrifugation at 20,000 x g, 4 ºC for 30 minutes. The resulting crude 
cytosol (supernatant) was filtered through a 20 micron Millipore syringe filter and then 
loaded onto a tandem anion exchange column (Source 15Q (GE healthcare); 20 ml) and 
cation exchange column (Source 15S (GE healthcare); 8 mL) pre-equilibrated in 20 mM 
HEPES pH 8.0. The column was washed with 3 column volumes (84 mL) of 20 mM 
HEPES pH 8.0. The anion exchange column was removed and purified E. coli PPCS was 
eluted with a linear gradient of 0-400 mM NaCl in 20 mM HEPES pH 8.0, with a total 
gradient volume of 80 mL. E. coli PPCS elutes as a single peak around 75 mM NaCl and 
was determined to be greater than 98% pure by SDS-PAGE. Fractions were combined 
desalted with Bio-Gel P2 column and concentrated using a Centricon 10,000 MW cutoff 
centrifugal filter unit and protein concentration was determined by absorbance at λ = 280 
nm (ε280 = 13,075 M
-1
 cm
-1
). 
Purification of E. faecalis PPCS. Cell suspension strain BL21-AI/pET23a::E. 
faecalis coaB was thawed then disrupted by French press at 20,000 psi and the insoluble 
debris was removed by centrifugation at 20,000 x g, 4 ºC for 30 minutes. The resulting 
crude cytosol (supernatant) was filtered through a 20 micron Millipore syringe filter and 
then loaded onto an anion exchange column (Source 15Q (GE healthcare); 8 ml) pre-
equilibrated in 20 mM HEPES pH 8.0. The column was washed with 3 column volumes 
(24 mL) of 20 mM HEPES pH 8.0. Purified E. faecalis PPCS was eluted with a linear 
gradient of 0-500 mM NaCl in 20 mM HEPES pH 8.0, with a total gradient volume of 80 
mL. Fraction were analyzed by SDS-PAGE and fractions containing PPCS were pooled 
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and passed through a 320 mL Superdex 200 prep grade column equilibrated in 20 mM 
HEPES pH 8.0 containing 150 mM NaCl. Purified fractions were desalted with Bio-Gel 
P2, subsequently concentrated using a Centricon 10,000 MW cutoff centrifugal filter unit 
and protein concentration was determined by absorbance at λ = 280 nm (ε280 = 28,415 M
-
1
 cm
-1
). 
Purification of his6 tagged S. pneumoniae PPCS. Cell suspensions were thawed 
and disrupted by French press at 20,000 psi and the insoluble debris was removed by 
centrifugation at 20,000 x g, 4 ºC for 30 minutes. The resultant crude cytosol was applied 
to a 2 ml Nickel column (Qiagen), equilibrated with 50 mM Imidazole, 20 mM HEPES 
pH 8.0. The column was washed with 5 column volumes of 500 mM NaCl, 50 mM 
Imidazole, 20 mM HEPES pH 8.0 followed by 3 column volumes of 50 mM Imidazole, 
20 mM HEPES pH 8.0. Histidine tagged enzyme was eluted from the column with 5 
column volumes of 250 mM Imidazole, 20 mM HEPES pH 8.0. The enzyme was then 
loaded onto a 2 ml Source 15Q column, washed with 3 column volumes of 20 mM 
HEPES pH 8.0 and eluted over a gradient of 0-500 mM NaCl. Purified PPCS was 
desalted on a Bio-Gel P2 column and analyzed by SDS-PAGE. Protein concentrations 
were determined by UV absorbance at λ = 280 nm (ε280 = 12,950 M
-1
 cm
-1
). 
Purification of untagged S. pneumoniae PPCS. Cell suspension strain BL21-
AI/pET23a::S. pneumoniae coaB was thawed then disrupted by French press at 20,000 
psi and the insoluble debris was removed by centrifugation at 20,000 x g, 4 ºC for 30 
minutes. The resulting crude cytosol (supernatant) was filtered through a 20 micron 
Millipore syringe filter and then loaded onto a tandem cation exchange column (Source 
15S (GE healthcare); 8 mL) and anion exchange column (Source 15Q (GE healthcare); 8 
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ml) pre-equilibrated in 20 mM HEPES pH 8.0. The column was washed with 3 column 
volumes (48 mL) of 20 mM HEPES pH 8.0. The cation exchange column was removed 
and protein was eluted from the anion exchange column with a linear gradient of 0-500 
mM NaCl in 20 mM HEPES pH 8.0, with a total gradient volume of 80 mL. Fractions 
were analyzed by SDS-PAGE, and those containing PPCS were collected, pooled, and 
concentrated to 2 mL using a Centricon 10,000 MW cutoff centrifugal filter unit. The 
protein was passed through a 320 mL Superdex 200 prep grade column equilibrated in 20 
mM TrisHCl pH 7.6 containing 10 mM NaCl. Fractions containing S. pneumoniae PPCS 
were combined concentrated using a Centricon 10,000 MW cutoff centrifugal filter unit 
to a protein concentration of 15 mg/mL. Protein concentration was determined by 
absorbance at λ = 280 nm (ε280 = 13,075 M
-1
 cm
-1
). 
Site directed mutagenesis. Site-directed mutagenesis was performed on the 
conserved catalytic residues determined by the multiple sequence alignment of bacterial 
PPCSs. The general method of mutagenesis followed that of the Quick Change Site-
directed Mutagenesis kit (Agilent) by using methylated plasmid DNA as a template. PRC 
amplification of the entire plasmid was performed using pUMKH7 (the vector containing 
the S. pneumoniae coaBC coding region) or pUMKH5 (the vector containing the E. coli 
coaBC coding region) as a template, and complementary primers (Table 2.2). The 
resultant mixture was then DpnI restriction digested which degraded all methylated 
plasmid. As pUMRJ100 has been introduced to bacteria, it will contain a dam methylated 
GATC site while the desired mutated DNA will not. The resultant plasmid was then 
transformed into E. coli XLI, which repaired nicks in the mutated plasmid and allowed for 
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amplification. The resultant plasmids were sequenced to verify that they contained the 
introduced mutations.  
Saturation mutagenesis and mutant selection criteria. Saturation mutagenesis was 
performed on selected conserved S. pneumoniae PPCS residues using NNK/MNN codon 
containing primers Table 2.3. PCR amplification of the pUMKH8 vector was performed 
under standard protocol with Pfu polymerase and the primers containing low-fidelity 
codons. In this process, the entire coaBC vector was PCR amplified, creating a pool of 
vectors containing a wide range of mutations at the single selected residue. This vector 
pool was transformed directly into the knockout strain KH100 and plated onto media 
containing 250 µM pantethine, allowing for the growth of all non-toxic mutations. 
Resultant colonies were streaked onto media with and without 250 µM pantethine in 
order to determine the growth phenotype (i.e. whether the mutation no longer was able to 
support growth without the addition of environmental pantethine). Plasmids were also 
isolated from these colonies and the specific point mutation was determined by 
sequencing at the University of Michigan Sequencing Core Facility.  
Mutants that were able to sustain cell growth under no pantethine conditions in 
the knockout model had their coaB (i.e. PPCS) domain PCR amplified and inserted into 
the pET23a vector following an NdeI. XhoI restriction enzyme digests. This vector was 
amplified in the XL1-Blue cell line and the sequence was verified at the University of 
Michigan Sequencing core. The vector was then transformed into the BL21-AI cell line 
and his-tagged protein expression and purification was performed as previously described 
(follows the S. pneumoniae PPCS-his6 protocol). 
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 Pyrophosphatase assay. The forward reaction of PPCS was monitored in real-
time through utilization of commercially available Pyrophosphate Reagent (Sigma 
Aldrich), coupling the PPCS production of pyrophosphatase with the oxidation of 
NADH, monitored by disappearance of absorption λ = 340 nm. In UV-visible 96-well 
half-area plates (Costar UV), 30 µL PR, an additional 1 U PPi-PFK, 10 mM DDT, and 
varying concentrations of cysteine, magnesium chloride, phosphopantetheine, and 
cytidine triphosphate, were incubated at 37 ºC in a final volume of 70 µL, buffered with 
50 mM Tris-HCl pH 7.6. After 10 minutes, 30 µL PPCS in 50 mM Tris-HCl pH 7.6 (pre-
incubated at 37 ºC) was added and absorbance readings were taken at λ = 340 nm for 10 
minutes using a SpectraMax M5. Activity of the enzyme was calculated by adjusting for 
pathlength (0.5 cm) and taking into account that each mole of pyrophosphate produced 
leads to the oxidation of 2 moles NDAH. Assays were run in triplicate, with average 
velocities reported. 
 Malachite green assay. Varying concentrations of the mutants and wild-type S. 
pneumoniae PPCS (5.0 µM, 2.5 µM, 1.0 µM, and 0.5 µM) we incubated for 15 minutes 
at 37 ºC in 50 µM CTP, 50 µM MgCl2, 150 µM phosphopantetheine, 150 µM cysteine, 
150 µM DTT, 20 mM HEPES pH 8.0 in a final volume of 40 µL. The reaction was 
quenched with 40 µL malachite green reagent (0.1125% malachite green carbinol 
hydrochloride, 2.1% ammonium molybdate, in 3 M hydrochloride), allowed to sit at 
room temperature for 5 minutes, then read at 600 nm in a SpectraMax M5. 
 Eikonogen assay. Metal dependence and pH experiments were performed using 
the Eikonogen assay, which allows for the direct quantification of pyrophosphate 
produced from the PPCS reaction. The reaction was quenched by the addition of 50 µL of 
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2.5% w/v ammonium molybdate in 5 N sulfuric acid, followed by the addition of 50 µL 
of 0.5 M β-mercaptoethanol and 20 µL of Eikonogen solution. The mixture was 
incubated at 37 ºC for 10 minutes, and then absorbance at 580 nm was read to quantify 
the amount of pyrophosphate produced (ε580 = 25,000 M
-1
 cm
-1
). 
 
Results and Discussion 
Growth studies of genetically complemented coaBC knockout strain. Using P1 
phage transduction and our lab’s previously generated E. coli MG1655 Δdfp 
(coaBC)::Kan
R
 and E. coli MG1655 ΔPanC::KanR mutant knockout strains, a double 
knockout E. coli ΔPanC,ΔcoaBC::KanR strain, designated KH100, was developed. The 
dfp gene is the monofunctional coaB-coaC gene in E. coli, and thus this knockout allows 
for the replacement of the coaB and coaC genes via a transformed vector’s expression. 
The PanC knockout allows for the control of cellular pantothenate levels as de novo 
pantothenate synthesis is halted and only environmental pantothenate will be utilized 
(14,15). Growth rates of pantetheine complemented KH100 are charted in Figure 2.2. At 
concentrations below 250 µM pantetheine, the double knockout exhibited a very long lag 
phase before entering a much slower logarithmic phase. At concentrations of 250 µM 
pantetheine and above, KH100 grows at the same rate as wild-type E. coli MG1655. Very 
high concentrations of pantetheine (10 mM) were determined to not be inhibitory to the 
growth of the double knockout strain. 
The genetically complemented E. coli model systems were characterized by 
growth rate in a variety of environments, including analysis of the effects of L-arabinose, 
dextrose, and pantothenate concentrations on growth. Interestingly, the pUMRJ100 
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plasmid appears to have loose enough regulation to allow for the expression of coaB-
coaC to levels necessary for survival, as knockouts containing each vector still grew 
under high dextrose, no L-arabinose conditions – a scenario which should normally limit 
the expression of the vector. Figure 2.3 shows growth curves for the genetically 
complemented E. coli. Growth rates of the genetically complemented knockout strains to 
wild type MG1655 were comparable. 
Using the knockout system to test MIC of inhibitors. In a proof of concept 
experiment, the double knockout model system KH100 was utilized in an MIC study 
against compound JY1 (ChemDiv SPB03328), the small molecule isoxazole discovered 
to inhibit PPCS in a previous high throughput screen (11). In an overnight study, the 
MIC50 for JY1 against E.coli, E. faecalis, and S. pneumoniae complemented double 
knockout was determined to be approximately 300 µg/ml (Figure 2.4). This shows that 
the compound is able to inhibit the growth of the complemented double knockouts in vivo 
in a concentration dependent manner. 
Further, a disc diffusion experiment was performed with JY1 against S. 
pneumoniae coaBC complemented KH100 and E. coli ΔtolC to give a more visual 
representation of the inhibitory activity of JY1 (Figure 2.5). With dextrose present to 
suppress plasmid expression, JY1 exhibited a zone of inhibition against both the 
supplemented knockout and ΔtolC cell line at 150 and 300 µg JY1. The addition of 100 
µM pantethine provided and environmental source of pantetheine for the knockout, and 
limited the zone of inhibition caused by JY1, indicating that antimicrobial activity of JY1 
is due to PPCS inhibition, further verifying the enzyme as a therapeutic target. In this 
manner, it would be possible to utilize KH100 in whole cell screens for antimicrobial 
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inhibitors of PPCS-PPCDC. The ability to rescue the knockout strain with pantetheine 
adds the element of rapid target validation. 
Multiple sequence alignment. To determine which residues are conserved among 
bacterial PPCS, several known bifunctional PPCS sequences were aligned with those of 
the three known bacterial monofunctional PPCS (Type 3) expressed in S. pneumoniae, E. 
faecalis, and Bacillus anthracis. Based on the moderate sequence homology of the 
proteins, it was possible to construct the alignment and quickly determine which residues 
are conserved and to what extent (Figure 2.6). A handful of residues were completely 
conserved across bacterial PPCS, including the N210 and K289 residues that were 
previously found to be essential to the catalytic activity of PPCS (6). 
In order to examine these residues in a structural sense they were mapped onto the 
E. coli PPCS structure, which was the only structure solved for bacterial PPCS. Figure 
2.7 shows the alignment of residues of the putative pockets of PPCS, and Figure 2.8 
shows these residues mapped onto the native E. coli crystal structure. Residues in E. coli 
that form the putative oxyanion hole, the divalent metal binding residue, and the CTP 
alpha phosphate binding residue (Asn210, Asp279, and Lys289 respectively) are highly 
conserved across all PPCS. Residues that make binding contacts with a divalent metal ion 
and the CTP alpha phosphate, important in the first half reaction of PPCS, are also 
conserved (6). While Gly214 and Lys385 in the phosphopantothenate phosphate binding 
pocket are conserved across all bacterial PPCS, residues Ser212 and Ser213 are not 
conserved in the monofunctional enzymes. However, the activity of conserved residues 
between the mono and bifunctional enzymes remained to be determined. 
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 In vivo model system for the evaluation of monofunctional PPCS. In order to 
quickly evaluate the viability of sited-directed mutants of S. pmeumoniae PPCS, a model 
system needed to be established. Using E. coli as the model organism would also confirm 
the validity of assumptions made from the multiple sequence alignment and the crystal 
structure of E. coli PPCS. By performing site directed mutagenesis on coaB of the coaB-
coaC containing vectors and transforming them into the double knockout KH100 strain, 
genetic mutants could be screened very quickly for their ability to support growth in an 
pantethine-free environment. 
 In a proof of concept experiment, vectors for E. coli PPCS(N210D)-PPCDC, 
PPCS(K289Q)-PPCDC, and PPCS(S212A)-PPCDC were generated. As mentioned 
earlier, Kupke identified the PPCS(N210D) mutation in E. coli as inactivating the first 
step cysteine condensation of PPCS (16). Additionally, the E. coli PPCS(K289Q) 
mutation inactivates the first step reaction, causing a build-up of phosphopantothenoyl 
cytidylate (16). The E. coli PPCS(S212A) mutation had no effect on catalysis and was 
selected as a control. These vectors were each separately transformed into KH100 and 
streaked onto media with and without pantethine. As expected, both E. coli 
PPCS(N210D)-PPCDC and PPCS(K289Q)-PPCDC resulted in a lethal phenotype 
without the presence of environmental pantetheine (Figure 2.9). This experiment was 
repeated with S. pneumoniae PPCS vectors PPCS(N22D)-PPCDC, PPCS(S24A)-
PPCDC, and PPCS(K123Q)-PPCDC (which align with E. coli PPCS mutations N210D, 
S212A, and K289Q). These vectors were also transformed into KH100 and streaked onto 
media with and without pantethine. S. pneumoniae PPCS(N22D)-PPCDC and 
PPCS(K123Q)-PPCDC expressed lethal phenotypes without the presence of 
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environmental pantethine. The matched phenotype of these point mutations in E. coli 
Type 1 PPCS and S. pneumoniae Type 3 suggest that these residues perform similar 
enzymatic roles. Initial mutagenesis performed on both E. coli coaB-coaC and S. 
pneumoniae coaB-coaC determined previously characterized mutations in E. coli PPCS 
have the same effect in the context of the bifunctional enzyme and the monofunctional 
enzyme. With a functioning model system, saturation mutagenesis could then be 
performed in S. pneumoniae for in vivo phenotypic evaluation of the mutants. 
 To determine if S. pneumoniae PPCS residue is responsible for the second half 
cysteine condensation (as it is in E. coli), S. pneumoniae PPCS(N22D), PPCS(S24A), and 
PPCS(K123Q) were overexpressed and purified. Varying concentrations of the mutant 
and wild-type S. pneumoniae PPCS (5.0 µM, 2.5 µM, 1.0 µM, and 0.5 µM) were assayed 
using the malachite green dye to calculate the pyrosphate released in the first half of the 
PPCS reaction (Figure 2.1). Wild-type S. pneumoniae PPCS produced approximately 10 
µM pyrophosphate regardless of the amount of enzyme in the assay, which would mean 
that the wild-type PPCS would have to perform multiple turnovers in order to produce 
more pyrophosphate than enzyme present (Figure 2.10). PPCS(S24A) produced 
approximately the same amount of pyrophosphate as the wild-type enzyme, further 
suggesting that the S22 residues doesn’t play a major role in catalysis. PPCS(K123Q) 
produced no pyrophosphate regardless of the amount of enzyme present, further verifying 
that the K123Q mutant completely inactivates S. pneumoniae PPCS as the first half 
reaction did not occur. PPCS(N22D) produced an amount of pyrophosphate roughly 
equivalent to the amount of enzyme present in the assay. This approximately 1:1 molar 
ratio of PPCS(N22D) present:pyrophosphate produced suggests a that each PPCS mutant 
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was able to perform a single turnover of the first half reaction. This would match with 
previous mutagenesis studies with E. coli PPCS(N210D), wherein PPCS(N210D) was 
able to produce the cytidylate intermediate but not phosphopantethoylcysteine (16). 
While not as robust at an HPLC aggregate study, this assay gave a quick indication that S. 
pneumoniae PPCS(N22D) could perform enough activity to produce some 
pyrophosphate, but not enough to complement the in vivo double knockout system. 
 Saturation mutagenesis of highly conserved bacterial PPCS residues. To continue 
investigating the conserved residues of S. pneumoniae PPCS, several conserved residues 
were targeted for saturation mutagenesis to determine their utility. These residues (Glu12, 
Asp15, Asp93, Lys123, Ser125, Ser126 and Lys213) were subjected to saturation 
mutagenesis in the S. pneumoniae PPCS-PPCDC vector (pUMKH7), transformed into 
KH100 and streaked onto pantethine-free media in order to determine their growth 
phenotype (Table 2.4).  
Residues 123, 125 and 126 compose a KxKK domain in Type I PPCS that is 
conserved as KxSS in the Type III enzyme. Lys125 aligns with the catalytic Lys289 of 
Type I PPCS that is responsible for the first half reaction (6). In vivo results support that 
this residue has a similar conserved role in S. pneumoniae PPCS, as only the K123M, 
K123N, and K123R mutations were viable. Residue 125 does not support mutations to 
other polar uncharged residues, but mutations to positively charged polar residues or 
hydrophobic residues are viable. The S125C mutation may be lethal due to cysteine 
interacting preferentially over Lys123, not allowing for catalysis of the first half reaction.  
 Residue Asp93 of S. pneumoniae PPCS aligns with Asp279, which appears to 
coordinate with the divalent cation Mg
2+
 in the active site of E. coli PPCS crystal 
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structures (Figure 2.9) (8,10). In vivo analysis supports that Asp93 plays an important 
role in the activity of S. pneumoniae PPCS, as only D93E and D93N were able to 
complement the double knockout model system (Table 2.4). A polar or negative charge 
is likely required at this position to coordinate with Mg
2+
, which is in turn coordinating 
with the phosphate backbone of CTP,  
 Other residues probed by saturation mutagenesis include to the completely 
conserved acidic residues Glu12 and Asp15. These residues supported a wide array of 
mutations. Glu12 can be substituted with any residue, and thus has no direct role on 
activity and is likely conserved as an optimized residue for structural stability. Asp15 
supported several diverse mutations, including arginine, glycine and cysteine. However, 
bulky residues (such as tryptophan) and hydrophobic residues (such as valine) were 
lethal, likely as a result of the mutation causing a protein misfolding rather than 
interfering directly with the catalysis of enzyme. Mapping these residues onto the E. coli 
PPCS crystal structure (Figure 2.6) shows that both E12 and D15 are closer to the dimer 
interface of PPCS and away from the cytidylate in the active site. 
 The completely conserved Lys213 was probed by saturation mutagenesis due to 
its close proximity to the pantothenoyl arm of the JDP03 in the E. coli crystal structure. 
Mutagenesis results revealed that K213 plays a minor role in activity. Of the residues that 
were found in the mutant pool, all of them were able to support growth of the knockout 
model. K213 supported both large and small hydrophobic residues, as well as aromatics. 
Resides that were not found in the mutant pool could be either to not enough coverage or 
due to toxicity of the mutation, but the high number of viable mutants suggests that the 
residue is more important structurally and not catalytic. 
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 In vitro analysis of S. pneumoniae PPCS mutants. To further characterize the 
activities of the selected conserved residues, in vitro analysis was performed by 
determining the enzymatic activity of each mutant. Following steady state Michaels-
Menten kinetics, apparent Michaels constants (Km) were determined for each mutant to 
each substrate. Wild-type S. pneumoniae PPCS was first characterized with the 
continuous pyrophosphatase assay as a reference point for the mutant apparent Km’s 
(Figure 2.11). The wild-type enzyme had a Km for CTP of 98.7 µM, Km for cysteine of 
391 µM, and a Km for phosphopantetheine (PPA) of 98.7 µM (Table 2.5). 
 The K123M, K123N, and K123R mutants were tested in the pyrophosphatase 
assay to determine apparent Km values for each substrate, and thus estimate the impact of 
K123 on substrate binding (Table 2.5). There appeared to me no significant trend of 
mutant effects with phosphopantetheine (Figure 2.12) and cysteine binding (Figure 
2.13). The Lys123 residue of Type 3 S. pneumoniae was believed to be responsible for 
mediating the phosphate activation of phosphopantothenate as Lys289 does in the E. coli 
enzyme.  In vitro analysis supports this as the K123M and K123R mutations had huge 
loss in the binding affinity of CTP (Figure 2.14), which is utilizes in the first step 
activation. Additionally, all three viable Lys123 mutations exhibited a large loss in the 
overall efficiency of the enzyme. 
The D93E and D93N mutants were also tested with the in vitro pyrophophatase 
assay for substrate apparent Km values (Table 2.5). Reside Asp93 of S. pneumoniae Type 
3 PPCS was believed to be largely responsible for coordinating Mg
2+
 into the active site 
to assist with the activation step from the crystal data. In vitro analysis supported this 
claim, as the D93E and D93N mutants had a 1.5-2.7 fold less affinity for CTP (Figure 
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2.17). Additionally, the Eikonogen assay was used to determine apparent Km values for 
the D93 mutants to MgCl2 (Figure 2.18). D93E was on par with wild-type S. pneumoniae 
PPCS, however D93N mutation had a much lower affinity for MgCl2. This is likely due 
to the long amino acid chain of asparagine compared to aspartate or glutamate to 
coordinate the Mg
2+
 thus hindering the activity of the enzyme. 
 
Conclusion 
This work represents the first molecular characterization of Type 3 PPCS. 
Through a novel multiple sequence alignment of strictly Type 1 and Type 3 PPCS, we 
were able to identify residues conserved completely across bacterial PPCS. The residues 
were mapped onto the available E. coli crystal structure, and highly conserved residues 
aligned with the active site (Figure 2.19). 
To probe these conserved residues for their roles in S. pneumoniae Type 3 PPCS, 
a double knockout system was developed which allowed for the rapid in vivo 
characterization of saturation mutant pools. Follow up in vitro characterization was 
performed on residues of interest to estimate the role of the residue based on its effect on 
substrate apparent Michaelis-Menten constants. 
Point mutation of N22 and K123 confirmed that they share the activities of N210 
and K289 in E. coli (Figure 2.19). K123 plays a catalytic role in the first half activation 
step, mediating the phosphate activation of pantetheine. N22 is believed to interact with 
cysteine and mediate the condensation in the second half reaction. Additionally, 
mutagenesis studies of D93 revealed that the residue plays an important role in 
associating the divalent cation, Mg
2+
, with the active site.   
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Table 2.1: List of vectors developed for the in vivo and in vitro characterization of bacterial PPCS. The parent plasmid and restriction digest sites 
used to construct the vector are also listed. The underlined portion of the primer is the recognition sequence for the corresponding restriction 
enzyme. 
Vector Insert Plasmid Digest Forward Primer (Top), Reverse Primer (Bottom)
pUMKH5 E. coli PPCS-PPCDC pUMRJ100 NdeI CGCGCATATGTCGCCCGTCAACGACCTGAAACATCTG
HindIII CGCGAAGCTTTTTAACGTCGATTTTTTTCATCATAACGGG
pUMKH6 E. faecalis PPCS-PPCDC pUMRJ100 NdeI GCGCCATATGGATGTTTTAGTTACTGCTGGCGG
NaeI ATATGCCGGCTTACTCCTTGTTATCAGATGC
pUMKH7 S. pneumoniae PPCS-PPCDC pUMRJ100 NdeI GCGCCATATGAGCCTGGCCGGTAAAAAAATCGTTCTCGGCG
HindIII CGCGAAGCTTTTAGAGCGTTTTTTCATCGATAGTTTCC
pUMKH32 H. sapien PPCS, pUMRJ100 NdeI CGCGCATATGGCAGAAATGGATCCGGTTGC
S. pneumoniae PPCDC HindIII CGCGAAGCTTTTAGAGCGTTTTTTCATCGATAGTTTCC
pUMDOT3 E. coli PPCS pET23a NdeI CGCGCATATGTCGCCCGTCAACGACCTGAAACATCTG
XhoI GCGCCTCGAGACGTCGATTTTTTTCATCATAACGGG
pUMGD1 E. faecalis PPCS pET23a NdeI GCGCCATATGGATGTTTTAGTTACTGCTGGCGG
XhoI GCGCCTCGAGTCATTGTTGTTCTCTCCATTTCTTTTC
pUMKH8 S. pneumoniae PPCS pET23a NdeI GCGCCATATGAAAATTTTAGTTACATCGGGCG
XhoI GCGCCTCGAGTTAAGAATGATAGGCTTGAATTTTTTC
pUMKH9 S. pneumoniae PPCS-his 6 pET23a NdeI GCGCCATATGAAAATTTTAGTTACATCGGGCG
XhoI GCGCCTCGAGAGAATGATAGGCTTGAATTTTTTC
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Table 2.2: List of vectors constructed for active site comparison of E. coli and S. pneumoniae PPCS. Codons used to insert the mutation are in 
bold on the listed primers. 
Vector Insert Plasmid Forward Primer (Top), Reverse Primer (Bottom)
pUMKH10 E. coli PPCS(N210D)-PPCDC pUMRJ100 CGGTGCGTTATATCTCTGATCACAGCTCCGGCAAG
CTTGCCGGAGCTGTGATCAGAGATATAACGCACCG
pUMKH11 E. coli PPCS(S212A)-PPCDC pUMRJ100 CGTTATATCTCTAATCACGCCTCCGGCAAGATGGGTTTTG
CAAAACCCATCTTGCCGGAGGCGTGATTAGAGATATAACG
pUMKH12 E. coli PPCS(K289Q)-PPCDC pUMRJ100 GCTACCGTGGCCCCAGAGCAGATCAAAAAGCAGGCCAC
GTGGCCTGCTTTTTGATCTGCTCTGGGGCCACGGTAGC
pUMKH13 S. pneumoniae PPCS(N22D)-PPCDC pUMRJ100 GCGTCCGCTCTATCACTGATCATTCTACAGGTCAC
GTGACCTGTAGAATGATCAGTGATAGAGCGGACGC
pUMKH14 S. pneumoniae PPCS(S24A)-PPCDC pUMRJ100 CGCTCTATCACTAACCATGCCACAGGTCACTTGGGG
CCCCAAGTGACCTGTGGCATGGTTAGTGATAGAGCG
pUMKH15 S. pneumoniae PPCS(K123Q)-PPCDC pUMRJ100 GCAAGCAAAATCATCAGGCCCAGATTTCTTCAACTGATG
CATCAGTTGAAGAAATCTGGGCCTGATGATTTTGCTTGC
pUMKH16 E. coli PPCS(N210D)-his 6 pET23a CGGTGCGTTATATCTCTGATCACAGCTCCGGCAAG
CTTGCCGGAGCTGTGATCAGAGATATAACGCACCG
pUMKH17 E. coli PPCS(S212A)-his 6 pET23a CGTTATATCTCTAATCACGCCTCCGGCAAGATGGGTTTTG
CAAAACCCATCTTGCCGGAGGCGTGATTAGAGATATAACG
pUMKH18 E. coli PPCS[K289Q]-his 6 pET23a GCTACCGTGGCCCCAGAGCAGATCAAAAAGCAGGCCAC
GTGGCCTGCTTTTTGATCTGCTCTGGGGCCACGGTAGC
pUMKH19 S. pneumoniae PPCS(N22D)-his 6 pET23a GCGTCCGCTCTATCACTGATCATTCTACAGGTCAC
GTGACCTGTAGAATGATCAGTGATAGAGCGGACGC
pUMKH20 S. pneumoniae PPCS(S24A)-his 6 pET23a CGCTCTATCACTAACCATGCCACAGGTCACTTGGGG
CCCCAAGTGACCTGTGGCATGGTTAGTGATAGAGCG
pUMKH21 S. pneumoniae PPCS(K123Q)-his 6 pET23a GCAAGCAAAATCATCAGGCCCAGATTTCTTCAACTGATG
CATCAGTTGAAGAAATCTGGGCCTGATGATTTTGCTTGC
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Table 2.3: List of vectors constructed in the mutagenesis studies of S. pneumoniae PPCS. Codons used to insert the mutation are in bold on the 
listed primer. 
Vector Insert Plasmid Forward Primer (Top), Reverse Primer (Bottom)
pUMKH25 S. pneumoniae PPCS(E12L)-PPCDC pUMRJ100 CATCGGGCGGTACCAGTCTGGCTATCGATAGCGTCCG
CGGACGCTATCGATAGCCAGACTGGTACCGCCCGATG
pUMKH26 S. pneumoniae PPCS(D15A)-PPCDC pUMRJ100 GTACCAGTGAAGCTATCGCGAGCGTCCGCTCTATCAC
GTGATAGAGCGGACGCTCGCGATAGCTTCACTGGTAC
pUMKH27 S. pneumoniae  PPCS(D93N)-PPCDC pUMRJ100 CACTCAATGGCTGTTTCTAACTACACTCCTGTTTATATG
CATATAAACAGGAGTGTAGTTAGAAACAGCCATTGAGTG
pUMKH28 S. pneumoniae PPCS(E12L)-his 6 pET23a CATCGGGCGGTACCAGTCTGGCTATCGATAGCGTCCG
CGGACGCTATCGATAGCCAGACTGGTACCGCCCGATG
pUMKH29 S. pneumoniae PPCS(D15A)-his 6 pET23a GTACCAGTGAAGCTATCGCGAGCGTCCGCTCTATCAC
GTGATAGAGCGGACGCTCGCGATAGCTTCACTGGTAC
pUMKH30 S. pneumoniae PPCS(D93N)-his 6 pET23a CACTCAATGGCTGTTTCTAACTACACTCCTGTTTATATG
CATATAAACAGGAGTGTAGTTAGAAACAGCCATTGAGTG
pUMKH31 S. pneumoniae PPCS(E12X)-PPCDC pUMRJ100 CATCGGGCGGTACCAGTNNKGCTATCGATAGCGTCCG
CGGACGCTATCGATAGCMNNACTGGTACCGCCCGATG
pUMKH32 S. pneumoniae PPCS(D15X)-PPCDC pUMRJ100 GTACCAGTGAAGCTATCNNKAGCGTCCGCTCTATCAC
GTGATAGAGCGGACGCTMNNGATAGCTTCACTGGTAC
pUMKH33 S. pneumoniae  PPCS(D93X)-PPCDC pUMRJ100 CACTCAATGGCTGTTTCTNNKTACACTCCTGTTTATATG
CATATAAACAGGAGTGTAMNNAGAAACAGCCATTGAGTG
pUMKH34 S. pneumoniae  PPCS(K123X)-PPCDC pUMRJ100 GCAAAATCATCAGGCCNNKATTTCTTCAACTGATGAGG
CCTCATCAGTTGAAGAAATMNNGGCCTGATGATTTTGC
pUMKH35 S. pneumoniae  PPCS(S125X)-PPCDC pUMRJ100 CAAAATCATCAGGCCAAGATTNNKTCAACTGATGAGGTTCAG
CTGAACCTCATCAGTTGAMNNAATCTTGGCCTGATGATTTTG
pUMKH36 S. pneumoniae  PPCS(S126X)-PPCDC pUMRJ100 CATCAGGCCAAGATTTCTNNKACTGATGAGGTTCAGGTTTTG
CAAAACCTGAACCTCATCAGTMNNAGAAATCTTGGCCTGATG
pUMKH37 S. pneumoniae  PPCS(K213X)-PPCDC pUMRJ100 GCTTCAAACAGTCCAGACTNNKGAAGAAATTGCAGAACTCC
GGAGTTCTGCAATTTCTTCMNNAGTCTGGACTGTTTGAAGC
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Residue E12 D15 D93 K123 S125 S126 K213 
Alanine (A) Grow Grow NG NG Grow - Grow 
Arginine (R) Grow Grow NG Grow Grow Grow - 
Asparagine (N) Grow - Grow Grow NG Grow Grow 
Aspartate (D) Grow Native Native NG NG Grow - 
Cysteine (C) Grow Grow NG NG NG Grow - 
Glutamate (E) Native Grow Grow NG - Grow - 
Glutamine (Q) Grow - NG NG NG - - 
Glycine (G) Grow Grow NG NG - - Grow 
Histidine (H) Grow NG NG NG Grow Grow Grow 
Isoleucine (I) Grow - NG NG Grow Grow Grow 
Leucine (L) Grow Grow NG NG Grow NG Grow 
Lysine (K) Grow - NG Native - - Native 
Methionine (M) Grow - NG Grow Grow - - 
Phenylalanine (F) Grow - NG NG Grow Grow Grow 
Proline (P) Grow NG NG NG Grow - - 
Serine (S) Grow Grow NG NG Native Native Grow 
Threonine (T) Grow NG NG NG NG NG Grow 
Tryptophan (W) Grow NG NG NG Grow - - 
Tyrosine (Y) Grow Grow NG NG NG Grow Grow 
Valine (V) Grow NG NG NG Grow Grow Grow 
 
Table 2.4: Phenotypes of S. pneumoniae PPCS mutants. Dashes indicate mutants not found in the 
pool of saturation mutagenesis.
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PPCS 
Mutant 
Km(CTP), 
µM 
Km(cysteine), 
µM 
Km(PPA), 
µM 
kcat
app
(PPA) 
(s
-1
) 
kcat
app
(PPA)/ 
Km(PPA) (s
-1
) 
Wild Type  98.7 ± 18.7 391 ± 17.8 99.3 ± 10.3 132 1.33 
D93E 151.0 ± 28.5 197.0 ± 18.1 150.1 ± 6.4 124 0.824 
D93N 266.5 ± 27.1 234.4 ± 11.8 247.9 ± 15.7 3.1 0.012 
K123M  142 ± 16.1 448 ± 23.0 181 ± 11.4 0.41 0.0022 
K123N  99.7 ± 12.3 305 ± 37.6 145 ± 17.2 0.22 0.0015 
K123R  872 ± 108 53.2 ± 9.0 211 ± 12.6 0.86 0.0040 
 
Table 2.5: Comparison of apparent Michaelis-Menten constants of S. pneumoniae PPCS mutants. 
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Figure 2.1: Two step reaction of PPCS. Bacterial PPCS utilize strictly CTP in the first step 
activation, whereas eukaryotic systems utilize ATP in addition to CTP.  
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Figure 2.2: Growth curve of knockout strain KH100 (E. coli MG1655 ΔPanC,ΔcoaBC::KanR) 
supplemented with various amounts of environmental pantetheine. 
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Figure 2.3: Growth curve of knockout strain KH100 genetically complemented with plasmid 
based coaBC domains from other organisms. Wild-type E. coli MG1655 and the uncomplemented 
knockout strain are also shown as controls. 
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Figure 2.4: MIC test of JY1 (SPB03328) against coaBC complemented KH100. Compound JY1 
was tested in an MIC study against the double knockout strain complemented with the coaBC 
domains of E. coli, E. faecalis, and S. pneumoniae. The compound exhibited comparable Minimal 
Inhibitory Concentration against each of the three complements. 
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Figure 2.5: Disc diffusion of JY1 against KH100 and E. coli ΔtolC. JY1 was tested against S. 
pneumoniae coaBC complemented double knockout on the two left columns, with and without 
supplemented pantethine. JY1 300 µg exhibited a ring of inhibition that was rescued by the 
addition of pantethine. JY1 was tested against tolC knockout (missing efflux pump) strain on the 
right two columns. The ring of inhibition is much larger, but still recovered by the addition of 
pantethine, indicating that JY1 is targeting the desired PPCS in its antimicrobial activity. 
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Figure 2.6: Full multiple sequence alignment of bacterial PPCS. Boxed and highlighted sequences represent the monofunctional Type 3 PPCS 
enzymes. The Type 1 PPCS are from the following species (in order top to bottom): Escherichia coli, Haemophilus influenzae, Pseudomonas 
aeruginosa, Bacillus anthracis Type 1 PPCS, Thermus aquaticus, Mycobacterium tuberculosis, and Helicobacter pylori. The Type 3 PPCS are 
highlighted in yellow and are from species as follows (in order from top to bottom): Streptococcus pneumoniae, Enterococcus faecalis, and 
Bacillus anthracis Type 3 PPCS. Bacillus anthracis contains both genes for Type 1 and Type 3 PPCS. 
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Figure 2.7: Selected conserved sequences found in the multiple sequence alignment between 
bacterial mono and bifunctional PPCS. Blue residues are highly conserved. Asterisks indicate 
residues that are part of the putative hydrophobic substrate cysteine pocket. Lines labeled in red 
represents the role those residues fulfill in E. coli according to structural data. Residues are 
labeled based on their position in E. coli in black and their position in S. pneumoniae PPCS in 
red. 
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Figure 2.8: Crystal structure of E. coli PPCS dimer (2.37 Å resolution) bound to cytidylate 
intermediate mimic. Highly conserved residues among all bacterial PPCS are rendered as stick 
figures. Residues of particular interest for mutagenesis probing are labeled with their equivalent 
residue number as expressed in S. pneumoniae PPCS.  
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Figure 2.9: Streaks of plasmid-based PPCS-PPCDC point mutations complementing KH100. 
E.coli PPCS mutants are listed on the left, and the corresponding S. pneumoniae PPCS mutation 
is listed on the right. 
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Figure 2.10: Results of single turnover assay in selected S. pneumoniae PPCS point mutations. 
The bold dotted line represents1:1 enzyme to pyrophosphate concentration, indicating that the 
enzyme is performing single turnover. 
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Figure 2.11: S. pneumoniae substrates Km curves. 
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Figure 2.12: S. pneumoniae PPCS K123 mutants phosphopantothenate apparent Km curves. 
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Figure 2.13: S. pneumoniae PPCS D93 mutants cysteine apparent Km curves. 
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Figure 2.14: S. pneumoniae PPCS K123 mutants cytidine triphosphate apparent Km curves. 
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Figure 2.15: S. pneumoniae PPCS D93 mutants phosphopantothenate apparent Km curves. 
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Figure 2.16: S. pneumoniae PPCS D93 mutants cysteine apparent Km curves. 
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Figure 2.17: S. pneumoniae PPCS D93 mutants cytidine triphosphate apparent Km curves. 
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Figure 2.18: S. pneumoniae PPCS D93 mutants MgCl2 apparent Km curves. 
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Figure 2.19 Active site of bacterial PPCS. In green is the co-crystal structure of native E. coli 
PPCS with JDP03 (in white) overlaid with 1U7W (teal), the structure of E. coli PPCS(N210D) in 
complex with CTP (yellow and orange). Residues highlighted are the conserved residues from S. 
pneumoniae PPCS.  
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Chapter 3 
Molecular binding mechanism of RJPXD33 to early Raetz pathway acyltransferases 
 
Background 
An underexplored area in the arena of novel therapeutics advancement is in the 
research and development of single antimicrobials which are able to act upon multiple 
essential subcellular targets. Dual-targeting antimicrobial agents have been shown to 
reduce the frequency of selection of resistant mutants mediated by target mutation, due to 
the requirement of an organism to obtain multiple mutations in several targets in order to 
display clinically relevant resistance. One group of enzymes with very strong structural 
and functional relationships, and therefore amenable to a dual-targeting strategy, are 
acyltransferases found in bacterial lipopolysaccharide (LPS) biosynthesis.  
Lipid A is the essential oligosaccharide moiety of lipopolysaccharide (LPS), 
responsible for anchoring the moiety to form the outer monolayer of the outer cell wall 
membrane of Gram-negative bacteria (1-3). Lipid A is essential to growth in most Gram-
negative bacteria(4,5) and modification to lipid A plays a role in protecting the bacteria 
from environmental stress (2). During infection, released lipid A initiates the host-cell 
immune response via the TLR4-MD-2 complex (6-10). Overstimulation of this complex 
can occur and lead to septic shock and ultimately death (9,11,12). The requisite nature 
and toxicity of lipid A make its biosynthetic pathway an optimal target for antimicrobial 
chemotherapeutic discovery (5,13-16) . 
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 The biosynthesis of lipid A consists of nine consecutive enzymatic processes. 
Acyltransferase LpxA performs the first step through a thermodynamically unfavorable 
reaction, utilizing an acyl carrier protein (ACP) to acylate UDP-N-acetylglucosamine 
(UDP-GlcNAc) at the 3-hydroxyl, producing UDP-3-O-(R-3-hydroxymyristoyl)-N-
acetylglucosamine (Figure 3.1) (17,18). Subsequent deacylation of the N-acetyl moiety 
by LpxC provides the first committed step of lipid A biosynthesis and is a key regulatory 
step in the E. coli pathway (19-21). Acyltransferase LpxD utilizes ACP to catalyze the 
third reaction, acylating the free amine of the glucosamine ring (22).  A peptide inhibitor 
(RJPXD33; TNLYMLPKWDIP-NH2) was recently identified and demonstrated affinity 
for both LpxD and LpxA. Crystal structures have been solved of the LpxA-RJPXD33 
complex; however no structure has been solved for the LpxD-RJPXD33 complex. Both 
LpxA and LpxD are essential, cytosolic enzymes that contain significant sequence, 
structural, and functional homology with one another. 
The nine enzymatic steps of Lipid A are constitutive. The glucosamine core of 
lipid A tends to be conserved across Gram-negative organisms though there is a high 
variability in the length of acyl chains incorporated by LpxA and LpxD. Differences in 
these acyl chain lengths play an integral role in the recognition by the host-immune 
system. In several species of LpxA, single amino acid residues have been identified as 
“hydrocarbon rulers,” limiting the length of acyl chains allowed to bind and be utilized 
by the enzyme (23). Recently our lab obtained a crystal structure of RPJXD33 bound to 
E. coli LpxA, wherein L6 of the peptide is within 2.8 Å of LpxA histidine 191, which has 
previously been identified as the hydrocarbon ruler. 
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Herein, acyltransferase binding studies utilizing various derivatives of RJPXD33 
were undertaken in order to investigate key residues for binding of RJPXD33 to LpxD 
and discover how the peptide’s structure dictates its dual inhibitor nature. Specifically, 
alanine scanning was performed on RJPXD33 to determine the contribution of each 
residue to the overall binding of LpxA and LpxD, and the residues important to the 
binding of both proteins. Additionally, residues responsible for the unique recognition of 
LpxA or LpxD were identified. Truncations of the RJPXD33 peptide were also made at 
the C-terminus in order to determine the minimum sequence necessary to inhibit LpxD. 
Additionally, peptide photo-affinity probes were crosslinked to LpxD in attempts to 
validate binding model of RJPXD33-LpxD with high resolution mass spectrometry. 
 RPJXD33 and RJPXD33cΔ6 provide for a direct and competitive binging assay 
that has been tested in E. coli acyltransferases thus far. Through characterization of these 
peptides ability to bind non-E. coli acyltranserases, it may be possible to extend 
fluorescence polarization competitive assays as a viable high throughput method for the 
rapid identification of broad spectrum LpxA and LpxD inhibitors.  
 
Materials and Methods 
Materials. LB (Lennox) broth and agar were purchased from Difco. Benzonase 
was purchased from Novagen. Sephedex G-10 gel filtration media was purchased from 
MP Biomedicals.  Bio-Rad Protein assay and BioGel P2 size exclusion gel was purchased 
from Bio-Rad. Ellman’s Reagent and Streptavidin-coated resin were purchased from 
Thermo Fisher/Pierce. All buffers and antibiotics were purchased in the highest grade 
from Sigma Aldrich or Fisher Scientific. 
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Cloning of E.coli lpxC, acpP, acpS, Vibrio harveyi aasS, and lpxA and lpxD from 
various bacterial species. PCR protocols were carried out under standard conditions 
utilizing Pfu DNA Polymerase and DNA obtained from Acinetobacter baumannii, 
Chlamydophila pneumoiae, Chlamydua trachomatis, Escherichia coli, Helicobacter 
pylori, Neisseria meningitidis, Porphyromonas gingivalis, and Pseudomonas aeruginosa. 
To perform the amplifications of the individual genes, primers used are found in Table 
3.1. Amplified PCR products for lpxA, and acpP were cloned into pET24a using NdeI 
and XhoI restriction sites. Vectors containing a his6-lpxD were inserted into a pET23a 
plasmid that was modified with the addition of a his-tag encoding region with a PmeI 
(CACGTG) site inserted into the original NdeI/HincII. Plasmids were transformed into E. 
coli XL-1 Blue cells for amplification and plasmids isolated from these cells were 
sequenced at the University of Michigan Sequencing Core Facility. Plasmids with 
confirmed sequences were transformed to create the E.coli expression strains found in 
Table 3.1. 
Proposed lpxA and lpxD were PCR amplified and individually cloned into 
pET23a using NdeI and XhoI restriction sites. All plasmids were transformed into E. coli 
XL-1 Blue cells for amplification and plasmids were isolated from these cell lines were 
sequenced at the University of Michigan Sequencing Core Facility. To construct 
expression strains, confirmed lpxA plasmids were transformed into BL21-AI and 
confirmed lpxD plasmids were transformed into Rosetta (DE3)/pLysS. 
Purification of holo-ACP. Following a modified protocol from Broadwater and 
Fox, as published by Jenkins et. al. (24), holo-ACP was prepared. An overnight starter 
culture of BL21-AI/pET24a::acpP/pET23a::acpS-his6 was used to inoculate 500 ml LB 
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media containing 50 µg/ml Ampicillin, 35 µg/ml Kanamycin. The cell culture was 
incubated at 37 ºC with shaking at 250 rpm until an OD600 of approximately 0.6 was 
reached. Protein expression was then induced by quickly cooling the culture to 18 ºC, 
then adding 1 mM IPTG, 0.07% L-arabinose. The culture was allowed to grow overnight 
(at least 14 hours) at 18 ºC with shaking at 250 RPM. Cultures were then cooled and 
harvested by centrifugation at 5,000 x g, 4 ºC for 10 minutes. Cells were resuspended in 
20 ml of 20 mM HEPES pH 8.0, 1mM TCEP and then disrupted by French press at 
20,000 psi. To the cellular lysate, 20 ml of cold isopropanol was slowly added while 
gently mixing at 4 ºC for 1 hour. The resulting suspension was centrifuged at 20,000 x g, 
4 ºC for 30 minutes. The supernatant was collected and gently mixed with 40 ml of 20 
mM HEPES pH 8.0, 1 mM TCEP and then loaded onto a Source 15Q column (8 ml) pre-
equilibrated with 20 mM HEPES pH 8.0, 1 mM TCEP. A 100 ml gradient of 20 mM 
HEPES pH 8.0, 1 mM TCEP containing 0-500 mM NaCl was performed and holo-ACP 
eluted at approximately 300 mM NaCl as determined by SDS-PAGE. The protein was 
then desalted on a P2 Bio-Gel column in 20 mM HEPES pH 8.0, 1 mM TCEP. Purified 
holo-ACP was lyophilized and stored at -20 ºC. Protein concentrations were measured via 
BioRad protein assay. 
Purification of E. coli LpxA-his6. An overnight starter culture of BL21-
AI/pET23a::lpxA-his6 was used to inoculate 2x250 ml LB (Lennox) media containing 50 
µg/ml Ampicillin. The culture was incubated at 37 ºC with shaking at 250 rpm until an 
OD600 of approximately 0.6 was reached. The culture was induced with 1 mM IPTG. 
0.07% L-Arabinose and allowed to further incubate at 37 ºC for 4 hours post-induction.  
Cultures were then cooled and harvested by centrifugation at 5,000 x g, 4 ºC for 10 
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minutes. Cells were resuspended in 10 ml of 10% glycerol, 20 mM HEPES pH 8.0 and 
stored at -80 ºC. Cell suspensions were thawed and disrupted by French press at 20,000 
psi and the insoluble debris was removed by centrifugation at 20,000 x g, 4 ºC for 30 
minutes. The resultant crude cytosol was applied to a 2 ml Nickel column (Qiagen), 
equilibrated with 50 mM Imidazole, 20 mM HEPES pH 8.0. The column was washed 
with 5 column volumes of 500 mM NaCl, 50 mM Imidazole, 20 mM HEPES pH 8.0 
followed by 3 column volumes of 50 mM Imidazole, 20 mM HEPES pH 8.0. Histidine 
tagged enzyme was eluted from the column with 5 column volumes of 250 mM 
Imidazole, 20 mM HEPES pH 8.0. The enzyme was then loaded onto a 2 ml Source 15Q 
column, washed with 3 column volumes of 20 mM HEPES pH 8.0 and eluted over a 
gradient of 0-500 mM NaCl. Purified LpxA was desalted on a Bio-Gel P2 column and 
analyzed by SDS-PAGE. Protein concentration was determined by Biorad Protein Assay 
via the microplate protocol and reconfirmed based on UV absorbance at 280 nm (ε = 
9190 M
-1
 cm
-1
). 
Purification of E. coli his6-LpxD. Previously generated E. coli expression strain 
Rosetta (DE3)/pLysS/pET23d::his6-LpxD were used to inoculate 500 ml TB media 
containing 50 µg/ml Ampicllin. The culture was incubated while shaking (250 rpm) at 37 
ºC until an OD600 of 0.6-1.0 was reached. The culture was induced with 1 mM IPTG and 
allowed to incubate at 37 ºC for 4 hours post-induction. The culture was then cooled and 
harvested by centrifugation at 5,000 x g, 4 ºC for 10 minutes. Cells were resuspended in 
10 ml of 10% glycerol, 20 mM HEPES pH 8.0 and stored at -80 ºC. Cell suspensions 
were thawed and disrupted by French press at 20,000 psi and incubated on ice with 25 
U/ml benzonase for 30 minutes. Insoluble debris was removed by centrifugation at 
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20,000 x g, 4 ºC for 30 minutes. The resultant crude cytosol was applied to a 3 ml Nickel 
column (Qiagen), equilibrated with 50 mM Imidazole, 20 mM HEPES pH 8.0. The 
column was washed with 5 column volumes of 500 mM NaCl, 50 mM Imidazole, 20 mM 
HEPES pH 8.0 followed by 3 column volumes of 50 mM Imidazole, 20 mM HEPES pH 
8.0. Histidine tagged enzyme was eluted from the column with 5 column volumes of 250 
mM Imidazole, 20 mM HEPES pH 8.0. The enzyme was then loaded onto a 2 ml Source 
15Q column, washed with 3 column volumes of 20 mM HEPES pH 8.0 and eluted over a 
gradient of 0-500 mM NaCl. Purified LpxD was desalted on a Bio-Gel P2 column and 
analyzed by SDS-PAGE. Protein concentrations were determined by Biorad Protein 
Assay via the microplate protocol and reconfirmed based on UV absorbance at 280 nm (ε 
= 27,305 M
-1
 cm-
1
). 
Purification of E. coli LpxC. An overnight starter culture of Rosetta 
(DE3)/pLysS/pET23a::lpxC-his6 was used to inoculate 2x250 ml TB media containing 50 
µg/ml Ampicillin, 20 µg/ml Chloramphenicol. The culture was incubated at 37 ºC with 
shaking at 250 rpm until an OD600 of approximately 0.6 was reached. The culture was 
induced with 1 mM IPTG and allowed to further incubate at 37 ºC for 4 hours post-
induction.  Cells were cooled on ice, and then harvested by centrifugation at 5,000 x g for 
10 min at 4 ºC. The cells were then resuspended in 10 ml of 20 mM HEPES pH 8.0, 10 % 
glycerol, and either immediately lysed or frozen and stored at -80 ºC until ready for lysis. 
The cell suspension was disrupted by at 20,000 psi, then incubated on ice for 30 minutes 
with 25 U/ml benzonase. Insoluble cell debris was then removed by centrifugation at 
20,000 x g, 4 ºC for 30 minutes. Soluble protein was loaded onto a 3 ml Ni-NTA 
(Qiagen) column pre-equilibrated in 20 mM HEPES pH 8.0, 50 mM imidazole. The 
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column was washed with 10 column volumes of 20 mM HEPES pH 8.0, 50 mM 
imidazole, 500 mM NaCl followed by 3 column volumes of 20 mM HEPES pH 8.0, 50 
mM imidazole. Purified protein was then eluted with 20 mM HEPES pH 8.0, 250 mM 
imidazole, desalted on a Gio-Gel P2 column, and analyzed by SDS-PAGE. Concentration 
of E. coli LpxC-his6 was determined by UV absorbance at 280 nm (ε = 22,920 M
-1
 cm-
1
). 
Purification of V. harvey AasS-his6. A 2 ml overnight starter culture of BL21-
AI/pET23a::aasS-his6 was used to inoculate 2x250 ml LB media containing 50 µg/ml 
Ampicillin. The cells were incubated at 37 ºC with shaking at 250 rpm until an OD600 of 
approximately 0.6 was reached. Cultures were induced with 1 mM IPTG and 0.07% L-
arabinose and allowed to incubate at 37 ºC for 4 hours post-induction. Cells were cooled 
on ice, and then harvested by centrifugation at 5,000 x g for 10 min at 4 ºC. The cells 
were then resuspended in 10 ml of 20 mM HEPES pH 8.0, 10 % glycerol, and either 
immediately lysed or frozen and stored at -80 ºC until ready for lysis. The cell suspension 
was disrupted by at 20,000 psi, then incubated on ice for 30 minutes with 25 U/ml 
benzonase. Insoluble cell debris was then removed by centrifugation at 20,000 x g, 4 ºC 
for 30 minutes. Soluble protein was loaded onto a 3 ml Ni-NTA (Qiagen) column pre-
equilibrated in 20 mM HEPES pH 8.0, 50 mM imidazole. The column was washed with 
10 column volumes of 20 mM HEPES pH 8.0, 50 mM imidazole, 500 mM NaCl 
followed by 3 column volumes of 20 mM HEPES pH 8.0, 50 mM imidazole. Protein was 
then eluted with 20 mM HEPES pH 8.0, 250 mM imidazole, and analyzed by SDS-
PAGE. Purified protein was desalted on a Bio-Gel P2 column in 20 mM Tris-HCl pH 7.5, 
10% glycerol, 1 mM EDTA, 0.1 mM TCEP, 0.002% Triton-X100, aliquoted into 
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microfuge tubes and stored at -80 ºC for optimal storage (25). Concentration for V. 
harvey AasS-his6 was determined by UV absorbance at 280 nm (ε = 65,780 M
-1
 cm
-1
). 
Fmoc-Photoleucine. Fmoc-PhotoLeu was synthesized as previously described 
(26). A 100 ml round bottom flask was covered with aluminum foil and kept on ice. In 
the flask, 200 mg PhotoLeu (1.4 mmol) and 236 mg sodium bicarbonate (2.8 mmol) were 
dissolved in 20 ml H2O. In 10 ml of THF, 708 mg Fmoc-OSu (2.1 mmol) was dissolved 
and added dropwise over 15 minutes into the PhotoLeu solution. The slurry was allowed 
to stir on ice for 10 minutes, and then stirred at room temperature for 8 hours. The flask 
was then placed on ice and the reaction quenched by adding 75 ml of 1:2 water:ethyl 
acetate followed by acidification to pH 2 with the dropwise addition of HCl. The product 
was extracted three times with 50 mL ethyl acetate. The organic layer was collected and 
applied to a rotary evaporator in order to concentrate the product. Resulting white solid 
was purified by flash chromatography with 1% methanol (v/v) and 1% acetic acid (v/v) in 
dichloromethane. The product was obtained as a white solid (440 mg, 86%). 1H NMR 
(400 MHz, DMSO) d 12.70 (s, 1H), 7.87 (d, J = 7.5, 2H), 7.71 (dd, J = 7.6, 4.4, 3H), 7.39 
(t, J = 7.4, 2H), 7.30 (t, J = 7.4, 2H), 4.38 - 4.16 (m, 3H), 3.89 - 3.76 (m, 1H), 1.93 - 1.81 
(m, 1H), 1.63 (dd, J = 14.8, 10.8, 1H), 0.99 (s, 3H). HRMS ESI+: calculated for [M+Na]+, 
388.1278; observed 388.1276.  
Fluorescence Polarization (FP) Assay. Peptides were synthesized as previously 
reported for solid phase peptide synthesis (2). The FP assay was performed as previously 
described (3).In 384-well black Costar plates, His6-LpxD and iodoacetamide treated His6-
LpxD were serially diluted while holding FITC-RJPXD33 at 20 nM in a final volume of 
50 µL in 20 mM HEPES pH 8.0, 0.01% Triton-X100. The wells were gently mixed and 
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incubated in the dark at 30 ºC for 15 minutes in a SpectraMax M5 plate reader. 
Polarization was measured by the plate reader in triplicate with readings taken at λex = 
485 nm and λem = 525 nm. The binding data was first fit to a standard binding isotherm 
(eq 1) with KaleidaGraph: 
                  
   
      
   
where mP is the experimentally determined polarization, mPf is the polarization of free 
FITC-RJPXD33, [P] is the total acyltransferace concentration, Kd is the dissociation 
constant of peptide-protein complex, and mPb is the polarization value of the fully bound 
fluorescent peptide. The calculated mPb was used to normalize the experimental data in 
order to fit the binding curves to the Hill equation (eq. 2): 
  
 
   
  
 
 
   
   
  
 
  
where α is the fraction of bound fluorescent peptide, [P] is the concentration of 
acyltransferase, Kd is the dissociation constant of the protein-peptide complex, and h is 
the Hill coefficient. 
Competitive Binding Assay. Varying concentrations of unlabeled peptides were 
incubated for 10 minutes at 30 ºC with 220-660 nM acyltransferase (concentration held at 
the Kd determined for the fluorescent tracer). Fluorescent tracer was then added to a final 
concentration of 20 nM, and the mixture was further incubated for 10 minutes. 
Polarization was then measured by the SpectraMax M5 plate reader in triplicate with 
readings taken at λex = 485 nm and λem = 525 nm. The [I]50 was determined from the 
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competition binding curve and the dissociation constant of the unlabeled ligand was 
calculated as previously described using eq. 3: 
   
     
     
  
 
    
  
  
 
where [I]50 is the unlabeled peptide concentration at 50% inhibition, [L]50 is the free 
ligand (fluorescent tracer) concentration at 50% inhibition, [P]0 is the free protein 
concentration at 0% inhibition, Kd is the dissociation constant of the fluorescent tracer, 
and Ki is the calculated dissociation constant for the unlabeled ligand. 
Iodoacetamide Modification. Iodoacetamide (10 mM) was incubated in the dark 
at room temperature with LpxD (150 µM) in 20 mM HEPES pH 8.0 at a final volume of 
500 µL for 45 minutes. The reaction was subsequently loaded onto a 3 ml BioGel P2 size 
exclusion column equilibrated with 0.1 M Tris-HCl pH 7.5.  The acylated protein was 
eluted with 0.1 M Tris-HCl pH 7.5, collected in 50 µL fractions, and monitored by the 
Bio-Rad Protein Reagent. Protein fractions were combined and concentrated via 
ultrafiltration in a Microcon YM-10 concentrator (Millipore) to a final concentration of 
244 µM and kept on ice until use in the assays. 
Ellman’s Assay. In a polystyrene semi-micro cuvette (Brandtech), 0.12 mg of 
LpxD or iodoacetamide treated LpxD was diluted to a final volume of 980 µL in 0.1 M 
Tris-HCl pH 7.5. with or without 5.3 M urea. The protein was incubated at room 
temperature for 5 minutes then 20 uL of 10 mM Ellman’s reagent in 50 mM HEPES pH 
7.0 and mixed by inversion. Subsequently, the absorbance of the solution was read at 412 
nm, blanked against the solution containing no protein, in a SpectraMax M5 for 10 
minutes. The absorbance readings plateaued by 10 minutes and the max absorbance 
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reading was used to determine the number of modified sulfhydryls using Beer-Lambert’s 
Law and a molar extinction coefficient of 13,600 M
-1
 cm
-1
. 
Covalent Crosslinking of Photoaffinity Probes to LpxA and LpxD. On ice in clear 
96-well half-area plates, 24 µM photoactivatable peptides were incubated with 10 µM 
acyltransferase in the presence or absence of 150 µM unlabeled peptide in a final volume 
of 30 µL in 20 mM HEPES pH 8.0 (DMSO 1% v/v). Plates, remaining on ice, were 
irradiated at λ = 365 nm for 10 minutes using a UV lamp (UVP model UVGL-58) at a 
distance of ~2 cm. Gel loading buffer was added directly to the samples, which were 
subsequently loaded and run on a 12% Tris-glycine SDS-PAGE gel. Gels were washed 
three times for 20 minutes at room temperature with deionized water to remove SDS. 
Fluorescein-labeled peptides were analyzed for in-gel fluorescence using a Typhoon 9400 
imaging system set to fluorescein wavelength (λex = 485 nm and λem = 525 nm), PMT 
sensitivity at 500 and pixel size at 50 microns. Resulting data was visualized using 
ImageQuant 5.2 software (RSBS-ANU). Following in-gel fluorescence, analysis, gels 
were stained using SimplyBlue SafeStain (Invitrogen). 
Identification of crosslinked photoaffinity probes to LpxD protein fragments. On 
ice in clear 96-well half-area plates, 10 µM photoactivatable peptides were incubated 
with 10 µM acyltransferase in a final volume of 4 aliquots of 30 µL in 20 mM HEPES 
pH 8.0 (DMSO 1% v/v). Plates, remaining on ice, were irradiated at λ = 365 nm for 15 
minutes using a UV lamp (UVP model UVGL-58) at a distance of ~2 cm. Following 
irradiation, these aliquots were loaded and run on a 12% Tris-Glycine SDS-PAGE gel. 
Gels were washed 3 times with water and the protein band was stained with Coomassie 
Brilliant Blue. The single protein bands were isolated, excised, and transferred to a 
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microcentrifuge tube that was pretreated with 0.1 % TFA in 50% Acetonitrile. In-gel 
Trypsin digest was performed using the Sigma protocol: Gel pieces were washed twice at 
37 C for 30 minutes with 200 µL of 20 mM ammonium bicarbonate in 40% acetonitrile. 
Gel pieces were dried in a Speed Vac, then digested overnight at 37 C by the addition of 
0.4 µg of Typsin in 70 µL 40 mM ammonium bicarbonate in 9% acetonitrile. Protein 
fragments were loaded directly onto an HPLC column and separated on a gradient of 5-
95% acetonitrile over 35 minutes at a flow rate of 1 ml/min. Fractions were monitored at 
λ = 490 nm and peaks were lyophilized, resuspended in 20 µL deionized water, and 
submitted for LC-UV-MS. Concentrations of the peaks estimated based on the 
absorbance of fluorescein at λ = 490 nm (ε = 8300 M-1 cm-1). 
 
Results and Discussion 
Activity of truncated RJPXD33. Determining the shortest chain length of the 
peptide is important for peptidomimetics as it provide the smallest scaffold with highest 
potency. To accomplish this, a series of C and N-terminally truncated peptides were 
synthesized and tested for binding to E. coli LpxA and LpxD. 
 Previously, Ronald Jenkins performed N-terminal truncations of RJPXD33 
(Table 3.2) (27,28). From his findings, RJPXD33(NΔ1) caused a complete loss of 
binding to LpxA. Thus, it was determined that residue Thr1 is essential to the binding of 
the peptide to the acyltransferase. As such, it was not necessary to test the remaining 
peptide series against LpxA, as none contained the essential Thr1. N-terminal truncations 
of RJPXD33 had a much less dramatic impact on LpxD binding. Loss of the N-terminal 
TN had little impact on binding. Truncation of Leu3 caused a 7.5-fold decrease in 
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binding affinity to LpxD, and truncation of Tyr4 resulted in a complete loss of binding to 
LpxD. 
 To complete the peptide truncations study, C-terminal truncations were 
synthesized and tested for binding potency to E. coli LpxA and LpxD (Table 3.2). Unlike 
the N-terminal truncations, C-terminal truncations of RJPXD33 had little overall effect 
on the binding of the peptide to LpxA. Truncations up to RJPXD33(CΔ3) had had similar 
binding affinity (5.7 μM) as the full length peptide (4.4 μM). Peptide RJPXD44(CΔ4) 
exhibited a 3-fold loss in potency, which could be a result of unfavorable interactions of 
the exposed basic Lys8. Truncation to RJPXD33(CΔ5) exhibited a further loss of binding 
affinity to LpxA, which may be a result of the placement of the exposed Pro7, because 
truncation to RJPXD33(CΔ6) increased potency, back to a 10.5 μM Kd to LpxA. This 
minor loss in overall binding affinity to LpxA indicates that only the six N-terminal 
residues of RJPXD33, equivalent to RJPXD33(CΔ6), are required for binding. 
 C-terminally truncated peptides were also tested against E. coli LpxD. Initial C-
terminal truncations had a beneficial impact on affinity to LpxD, as RJPXD33(CΔ3) 
bound 4-fold more tightly (0.5 μM) to the acyltransferase than the full length peptide. 
This is an indication that Asp10 isn’t forming any major interaction in the peptide-LpxD 
complex, as loss of Asp10 increased binding affinity. Truncations past Trp9 
demonstrated a decrease in binding to LpxD, with RJPXD33(CΔ6), exhibiting a Kd 
greater than 50 μM. From these truncation studies, it appears that the shortest peptide to 
exhibit high affinity to LpxD would be RJPXD33(NΔ2, CΔ3): YMLPKW. The shortest 
peptide to exhibit dual affinity to LpxA and LpxD would be RJPXD33(CΔ3): 
TNLYMLPKW.  
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 Effects of C-terminal carboxylic acid on the binding of FITC-RJPXD33 
truncations. Through the utilization of Wang resin rather than Rink amide resin, it was 
possible to synthesize a series of FITC-labeled peptides with a C-terminal carboxylic 
acid. In this manner, it is possible to test the effects of a negative charge being moved 
through the RJPXD33 binding site. Thus, direct binding studies would highlight positions 
were the addition (or omission) of an acidic moiety would be beneficial in the rational 
design of a small molecule inhibitor of LpxA and LpxD. 
 Table 3.3 lists the direct binding results of these carboxylate-capped peptides 
against E. coli LpxA. Overall, this series of peptides bound slightly tighter to LpxA than 
FITC-RJPXD33 with the C-terminal amide, with the exception of FITC-RJPXD33(CΔ4)-
COOH. This drop in affinity could be due to the C-terminal carboxylic acid being 
adjacent to the basic Lys8, causing instability to the structure of the peptide as a whole, as 
this peptide had a similar loss in affinity to LpxD. FITC-β-TNLYML-COOH afforded the 
highest affinity to LpxA, with a 2.3-fold increase in affinity compared to FITC-
RJPXD33. The addition of the C-terminal carboxylic acid had an adverse effect on the 
affinity of FITC-RJPXD33 to LpxD. This would corroborate that RJPXD33 is binding to 
a hydrophobic region of LpxD, as the addition of an acidic moiety anywhere along the 6 
C-terminal residues of LpxD caused a loss in affinity. 
 Alanine-scan of RJPXD33. To further characterize the binding of RJPXD33, it 
was essential to determine which residues are responsible for binding to the 
acyltrasferases and selectivity between LpxA and LpxD. By systematically replacing each 
residue of the 12-mer RJPXD33 peptide with alanine and determining its new binding capacity to 
the acyltransferases, we obtain an estimation of how valuable the mutated residue is to the overall 
binding of the peptide. The results of these binding assays are presented in Table 3.4. 
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 A graphical representation of the affinity of the alanine series of peptides against 
E. coli LpxA is presented in Figure 3.2. Supporting the truncation studies, swapping 
Thr1 to and alanine caused a complete loss of affinity to LpxA. RJPXD33(L3A) and 
RJPXD33(Y4A) also exhibited complete loss of affinity for LpxA. RJPXD33(N2A) also 
exhibited a nearly 20-fold drop in binding affinity to LpxA. The large to complete loss of 
binding affinity from swapping these 4 C-terminal residues to alanine further highlights 
the essentiality of these residues in the RJPXD33-LpxA binding complex. 
Interestingly, Thr1 and Asn2 had little impact on the binding RJPXD33 to LpxD 
(Figure 3.3); however mutation of Leu3 caused a 7-fold drop in binding capacity. 
Moreover, Tyr4 is essential for the binding of the peptide to both LpxA and LpxD, as 
mutation of this residue to alanine caused the peptide to no longer bind either 
acyltransferase. The alanine mutations showed that each individual component of the 
YML motif is essential to the binding of the entire RJPXD33 peptide to LpxD. 
Additionally, mutation of Pro7 caused a nearly 45-fold drop in the binding efficiency to 
LpxD while having a nominal effect on the binding to LpxA. 
Mutation of Trp9 appeared to have a large impact on the binding of the peptide to 
both LpxA and LpxD (Figure 3.4), however this could be that the swapping of the bulky 
tryptophan to a much smaller alanine side chain places Lys8 and Asp10 into much closer 
proximity, allowing them to interact and develop secondary structure that would impede 
the binding of the peptide to the acyltransferases. 
Inhibitory effects of truncated and alanine-substituted peptides. In order to 
validate the binding of these peptides correlated with inhibition of the acyltransferases, 
the IC50 of each peptide was determined against both LpxA and LpxD. For this, the 
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forward direction of the acyltransferase was monitored using a previously developed 
continuous fluorescent assay (24).  
C-terminal truncations of RJPXD33 against both LpxA and LpxD caused a 
decrease in the potency of the peptide (Table 3.2) However, RJPXD33(CΔ3) had no 
decrease on potency when compared to the full length peptide. Thus, the C-terminal DIP 
are not required for activity of the peptide. 
Alanine-scan peptides further verified that the 6 N-terminal residues of RJPXD33 
are required for inhibitory activity against LpxA. Mutation of any of these residues to 
alanine resulted in at least a 5-fold drop in potency, though most caused the peptide to be 
completely ineffective. Interestingly, Trp9 is required for inhibitory activity of the full 
length peptide against LpxA. Additionally, Lys8 and Asp10 had little overall impact on 
inhibitory activity of RJPXD33. 
The alanine-scan peptides also highlighted the essential nature of the YML motif 
in binding and inhibiting LpxD, as mutation of any of these residues caused the peptide to 
be ineffective. Pro7 and Trp9 are integral to the potency of RJPXD33, as mutations of 
these residues cause a 20-fold loss of inhibition. Overlays of the LpxA and LpxD crystal 
structures suggest that Pro7 is important in bending the peptide into the groove toward 
the C-terminal α-helical extension of LpxD (28).  
From the truncation and alanine studies, we have learned that Trp9 is interacting 
with LpxA and LpxD in a manner intergral to inhibitory activity, which is significant as 
the 6 C-terminal residues of RJPXD33 did not have a density in the RJPXD33-LpxA 
crystal structure. In Figure 3.4, we have an overlay of the residue activities of RJPXD33 
against both LpxA and LpxD. It is quickly apparent that Lys8 has little impact on the 
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binding or inhibition of the overall peptide. Going forward, the shortest length. most 
potent peptide to inhibit both LpxA and LpxD is TNLYMLPAW. 
Crosslinking of Photopeptides to LpxD. Crystallographic data is available for 
RJPXD33-LpxA, but we were unable to obtain a structure of RJPXD33-LpxD. As an 
alternative to obtaining a crystal structure, a series of FITC-labeled photopeptides were 
synthesized. This series of peptides introduced a diarzine-containing leucine residue in 
place of Leu3 (Photo 1), Leu6 (Photo3), or Ile11 (Photo 4). By incubating the 
photopeptides with LpxA and LxpD and adding UV light to mixture, photo-leucine 
activates and forms a covalent bond with the protein, near the normal binding location of 
the peptide. From this FITC-photopeptide-protein linkage, the enzyme can be digested 
and the segment of enzyme linked to the FITC-photopeptide can be recollected and 
submitted to MALDI-MS. In doing so, we can identify the location the peptide binds the 
protein, and thus identify key residues in the molecular binding mechanism of the 
peptide. 
The first step in this endeavor was to test that the photopeptides could still bind 
LpxA and LpxD. Thus, direct bind FP assays were performed (Figure 3.5). These 
peptides were able to bind to LpxA and LpxD with similar affinity to that of RJPXD33 
(Table 3.5). As these peptides were able to bind LpxA and LpxD, they were tested for in-
gel fluorescence following crosslinking and SDS-PAGE. Photopeptides 1, 3, and 4, were 
all able to crosslink both LpxA and LpxD and exhibit in-gel fluorescence (Figure 3.6). 
These photopeptides bound in the same location as RJPXD33, as addition of the 
unlabeled peptide to the mixture was able to compete with the photopeptide crosslinking.   
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Iodoacetamide Modification of LpxD. To limit the amount of off target 
crosslinking of the photopeptides, acylation of cysteine residues of LpxD by 
iodoacetamide modification was investigated. First, the number of solvent exposed 
cysteine moieties of LpxD could be determined from Ellman’s Assay. For unmodified 
LpxD, the ratio in absorbance between denatured and native protein was calculated to be 
approximately 7:2. As there are 7 cysteine residues in LpxD, there are thus 2 solvent 
exposed cysteine residues that are open to sulfhydryl modification by DTNB in the native 
protein.  From the Ellman’s Assay of the urea denatured iodoacetamide treated LpxD, it 
was determined that approximately 5 of the 7 cysteine residues of LpxD were acylated.  
 The FP assay was performed on iodoacetamide treated LpxD to determine if 
acylation of the 5 exposed cysteines affected RJPXD33 binding (Figure 3.7). These 
residues do not appear to effect RJPXD33 binding, as the peptide was able to bind both 
native and acylated LpxD with roughly the same affinity (Kd = 2.8 µM for native LpxD, 
Kd = 3.1 µM for iodoacetamide treated LpxD).  
FITC-Photopeptides were crosslinked to both native and iodoacetamide modified 
LpxD. Excess peptide was washed away and the covalent photopeptide-LpxD complex 
underwent protein digest. The digested protein mixture submitted to HPLC, and the 
fraction containing the crosslinked photopeptide was collected by monitoring at 490 nm 
for the FITC moiety. These collected fragments were submitted to collaborators at the 
University of Michigan Biomedical Mass Spectrometry Facility for MALDI MS in order 
to determine the mass of these fragments. They were unable to obtain a mass for the first 
round of fragments. The process was scaled up and we are currently awaiting results. 
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Binding of RJPXD33 to acyltransferases from other organisms. In order to further 
utilize RJPXD33 as a chemical biological probe, the binding affinity of RJPXD33 was 
determined against a wide spectrum of gram negative bacteria, including Acinetobacter 
baumannii, Chlamydia pneumoniae, Chlamydia trachomatis, Helicobacter pylori, 
Neisseria meningitides, Porphyromonas gingivalis, and Pseudomonas aeruginosa. These 
represent LpxA and LpxD that incorporate varying length acyl chains into the 
glucosamine core. By testing RJPXD33 against this array, we can determine how broad 
spectrum the peptide scaffold offers and also the utility of RJPXD33 in screens for 
compounds against a wider array of bacterial species. 
There appeared to be no connection between the acyl-chain preference of the 
enzyme and the affinity of FITC-RJPXD33 to the enzyme, as both A. baumannii and N. 
meningitidis LpxA incorporate OH-C12 acyl chains, yet FITC-RJPXD33 a Kd 3.01 µM 
against A. baumannii LpxA and a Kd >100 µM against N. meningitidis LpxA. 
Additionally, the ability of RJPXD33 to bind the LpxA of a species does not guarantee it 
also binds the LpxD of that species. For example, FITC-RJPXD33 has a Kd 17.8 µM 
against P. aeruginosa LpxA, and a Kd >100 µM against P. aeruginosa LpxD. Overall, 
RJPXD33 does appear to be a useful broad spectrum chemical biological probe of Raetz 
acyltransferases, as it was able to bind most of the explored enzymes.  
 
Conclusion 
Through binding and inhibition studies of LpxA and LpxD with peptide 
RJPXD33 analogs, we were able to determine the key residues in the molecular binding 
mechanism of the peptide to the proteins. Through N-terminal truncations, we determined 
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that T1 is essential to binding to LpxA, and that the first N-terminus residue essential to 
LpxD recognition is M5. C-terminal truncations revealed that the 6 C-terminal residues 
have little impact on LpxA recognition, but loss of W9 causes a drop in IC50 from 27.4 
μM to 66.6 μM, against LpxA and a drop in IC50 from 3.2 μM to >100 μM against 
LpxD. This is likely due to the loss of a large, bulky group to assist in preventing the 
acyl-phosphopanetheine prosthetic arm of acyl-ACP from associating with the 
acyltransferase. Figure 3.8 are the crystal structures of LpxA-RJPXD33 (28) overlaid 
with that of LpxD-acyl-ACP (29), illustrating this space. This structural overlay also 
gives insight to the significance of P7, as substitution of the proline to alanine resulted in 
a 44-fold drop in affinity to LpxD (2.03 μM to 89.6 μM) and a 20-fold loss in inhibition 
of LpxD (3.2 μM to 64 μM). The proline is likely creating a vital hairpin turn in the 
peptide secondary structure, allowing W9 to occupy a more structurally relevant space.  
While TNLYML has been identified as the shortest peptide to bind both LpxA 
and LpxD with high affinity, TNLYMLPKW has been identified as the optimal peptide 
for high affinity binding and inhibition of both acyltransferases, with a sub 6 μM binding 
affinity to both LpxA (5.7 μM) and LpxD (0.5 μM), and inhibit LpxA with an IC50 of 
26.7 μM and LpxD with an IC50 of 2.4 μM. Alanine substitution elucidated that K8 
resulted in a slight improvement of inhibition of the full length peptide to LpxA (20.6 μM 
IC50). As a basic residue at this position appears to be of little inhibitory or biding 
consequence to either acyltransferase, TNLYMLPAW would be the best peptidic 
scaffold to begin rational design of small molecule dual targeting inhibitors. 
Additionally, FITC-RJPXD33 proved to be useful probe in investigating a 
broader spectrum of bacterial Raetz pathway acyltransferases. Interestingly, these 
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peptides appeared to be more useful as LpxA probes than LpxD, those this may have 
been in part due to difficulties in the expression and purification of Chlamydia and 
Helicobacter LxpD.  
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Table 3.1: List of vectors constructed for acyltransferases studies. 
  
Gene Plasmid Digest Forward Primer (Top), Reverse Primer (Bottom)
E. coli pET23a NdeI GCGCCATATGATTGATAAATCCGCCTTTGTGCATCCAACCGC
LpxA-his6 XhoI ATATCTCGAGACGAATCAGACCGCGCGTTGAGCGTGC
E. coli pET23a NdeI GCGCCATATGATGATCAAACAAAGGACACT
LpxC-his6 XhoI GCGCCTCGAGTGCCAGTACAGCTGAAGGCG
E. coli pET24d NcoI CATCACCATCACCATCACGCTCAATTCGACTGGCTGATTTAGCG
his6-LpxD XhoI CGCGCTCGAGTTAGTCTTGTTGATTAACCTTGCGCTC
E. coli pET23a NdeI GCGCCATATGAGCACTATCGAAGAACGCGTTAAGAAAATTATC
AcpP XhoI CGCGCTCGAGCGCCTGGTGGCCGTTGATGTAATCAATG
E. coli pET24a NdeI GCGCCATATGGCAATATTAGGTTTAGGCACGGATATTG
AcpS-his6 XhoI GCGCCTCGAGACTTTCAATAATTACCGTGGCACAAGC
V. harveyi pET23a NdeI GCGCCATATGAACCAGTATGTAAAT
aasS-his6 XhoI GCGCCTCGAGCAGATGAAGTTTACGCAG
A. baumannii pET23a NdeI GCGCCATATGAGCAATCACGATTTAATCC
LpxA-his6 XhoI GCGCCTCGAGGCGCACAATTCCACGCTCTG
A. baumannii pET23a PmlI GCGCCACGTGCAACAATATCGTTTAGATGAATTAGC
his6-LpxD XhoI GCGCCTCGAGTTATTTACGCAAATTAAAAGTTGATTC
C. pneumoniae pET23a NdeI GCGCCATATGGCGAGCATTCACCCAACTGC
LpxA-his6 XhoI GCGCCTCGAGAGATTCAATCAAAACTCCTTC
C. pneumoniae pET23a PmlI GCGCCACGTGTCTTAAACAGTTAGCTGAGC
his6-LpxD XhoI GCGCCTCGAGTTAGATCTCTGAAGGAATCTCAGC
C. trachomatis pET23a NdeI GCGCCATATGACCAACATTCATCCTACAGCG
LpxA-his6 XhoI GCGCCTCGAGTTAAGACTCAACGAAAGCTCCTTC
C. trachomatis pET23a NdeI GCGCCATATGATTGATAAATCCGCCTTTGTGCATCCAACCGC
his6-LpxD HindIII GCGCAAGCTTAATGTTGTTCTGAGAGAGC
H. pylori pET23a NdeI GCGCCATATGAGTAAGATTGCAAAAACAGCC
LpxA-his6 XhoI GCGCCTCGAGTTCCTCTTGTTTTTCTTCGC
H. pylori pET23a PmlI GCGCCACGTGTTAAGCGAATTGTTGAGCGCC
his6-LpxD XhoI GCGCCTCGAGTTAAGACTTAAAAAACCCTTTAGC
N. meningtidis pET23a NdeI GCGCCATATGACCCTCATCCACCCGACCG
LpxA-his6 XhoI GCGCCTCGAGGCGGATGATGCCGCGCGCCG
N. meningtidis pET23a PmlI GCGCCACGTGATTCCGGCCACCTACACCCTG
his6-LpxD XhoI GCGCCTCGAGTTATTTGCTGTCTTGACCGGCATC
P. gingivalis pET23a NdeI GCGCCATATGATGTCAGAGACAAAAATCAG
LpxA-his6 XhoI GCGCCTCGAGCTCCATGGTTCCGCGGACAATGC
P. gingivalis pET23a PmlI GCGCCACGTGGAATTTACAGCCCAACAGATAGC
his6-LpxD XhoI GCGCCTCGAGTTAGTGTTTGTTGTTTTTGCATATTTC
P. aeruginosa pET23a NdeI GCGCCATATGAGTTTGATCGATCCTCGCG
LpxA-his6 XhoI GCGCCTCGAGGCGGGTGATGCCGCGGGTTGCGC
P. aeruginosa pET23a PmlI GCGCCACGTGATGAGTACCTTGTCCTACACCCTGG
his6-LpxD XhoI GCGCCTCGAGTTACGCATCAGATGAAGCGTCACC
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Peptide Sequence 
LpxA Kd 
(µM) 
LpxA 
IC50 
LpxD Kd 
(µM) 
LpxD 
IC50 
RJPXD33 TNLYMLPKWDIP  4.4+ 0.4 27.4 ± 4.4 2.0 + 0.3 3.2 ± 0.08 
RJPXD33(NΔ1)  NLYMLPKWDIP  DNB N/A 1.6 + 0.2 N/A 
RJPXD33(NΔ2)  LYMLPKWDIP  N/A N/A 2.8 + 0.4 N/A 
RJPXD33(NΔ3)  YMLPKWDIP  N/A N/A 15.3 + 1.5 N/A 
RJPXD33(NΔ4)   MLPKWDIP  N/A N/A DNB N/A 
RJPXD33(CΔ1) TNLYMLPKWDI  4.0 + 0.2 79.0 ± 2.9 1.3 + 0.1 5.3 ± 0.6 
RJPXD33(CΔ2) TNLYMLPKWD  4.2 + 0.2 151 ± 1.4 1.2 + 0.1 10.8 ± 1.7 
RJPXD33(CΔ3) TNLYMLPKW  5.7 + 0.4 26.7 ± 1.2 0.5 + 0.1 2.4 ± 0.1 
RJPXD33(CΔ4) TNLYMLPK  12.7 + 0.8 66.6 ± 5.8 6.8 + 0.5 > 100 
RJPXD33(CΔ5) TNLYMLP  14.5 + 1.7 >200 14.6 + 1.3 >100 
RJPXD33(CΔ6) TNLYML  10.5 + 1.1 123 ± 26 > 50 µM >100 
 
Table 3.2: Kd and IC50 values of truncated peptides. 
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Sequence  C-Term LpxA Kd (µM) LpxD Kd (µM) 
FITC-β-TNLYMLPKWDIP  CONH 12.6 + 0.5 0.66 + 0.10 
FITC-β-TNLYMLPKWDI  COOH 6.8 + 0.9 3.8 + 1.0 
FITC-β-TNLYMLPKWD  COOH 7.8 + 0.2 5.2 + 0.3 
FITC-β-TNLYMLPKW  COOH 11 + 1.0 2.4 + 0.1 
FITC-β-TNLYMLPK  COOH 42.7 + 2.6 62 + 8.9 
FITC-β-TNLYMLP  COOH 6.2 + 0.1 18 + 2.3 
FITC-β-TNLYML COOH 5.4 + 0.3 36 + 3.5 
 
Table 3.3: Direct binding results of C-terminal carboxylic acid peptides. 
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Peptide Sequence 
LpxA Kd 
(µM) 
LpxA 
IC50 
LpxD Kd 
(µM) 
LpxD 
IC50 
RJPXD33 TNLYMLPKWDIP 4.35 ± 0.42 27.4 ± 4.4 2.03 ± 0.26 3.2 ± 0.08 
RJPXD33(T1A) ANLYMLPKWDIP DNB D.N.I. 12.8 ± 0.6 3.8 ± 0.3 
RJPXD33(N2A) TALYMLPKWDIP 81.3 ± 19.4 >200 17.0 ± 2.9 11.2 ± 1.7 
RJPXD33(L3A) TNAYMLPKWDIP DNB D.N.I. 78.9 ± 24.3 18.3 ± 2.5 
RJPXD33(Y4A) TNLAMLPKWDIP DNB D.N.I. DNB D.N.I. 
RJPXD33(M5A) TNLYALPKWDIP 23.9 ± 3.4 106 ± 32 DNB D.N.I. 
RJPXD33(L6A) TNLYMAPKWDIP 26.2 ± 4.3 >200 DNB D.N.I. 
RJPXD33(P7A) TNLYMLAKWDIP 9.4 ± 0.6 59.7 ± 9.6 89.6 ± 33.7 63.7 ± 7.7 
RJPXD33(K8A) TNLYMLPAWDIP 5.1 ± 0.4 20.6 ± 3.4 3.1 ± 0.2 9.8 ± 1.8 
RJPXD33(W9A) TNLYMLPKADIP 43.6 ± 5.2 D.N.I. DNB 78.6 ± 26.9 
RJPXD33(D10A) TNLYMLPKWAIP 1.8 ± 0.7 39.4 ± 12.3 1.6 ± 0.7 1.52 ± 0.04 
RJPXD33(I11A) TNLYMLPKWDAP 2.3 ± 0.4 68.8 ± 19.4 4.3 ± 0.3 18.2 ± 3.0 
RJPXD33(P12A) TNLYMLPKWDIA 58.0 ±3.5 >200 13.0 ± 1.7 16.7 ± 2.4 
 
Table 3.4: Kd and IC50 values of alanine-scan peptides. D.N.B. indicates the peptide did not 
exhibit binding, D.N.I. indicates that the peptide did not exhibit inhibition. 
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Peptide  Sequence LpxA Kd (µM) LpxD Kd (µM) 
Photo 1  TNXYMLPKWDIP 37.4 + 2.42 2.07 + 0.30 
Photo 3  TNLYMXPKWDIP 32.1 + 3.28 1.09 + 0.11 
Photo 4  TNLYMLPKWDXP 20.3 + 1.75 0.80 + 0.15 
FITC-RJPXD33  TNLYMLPKWDIP 20.0 + 1.5 0.60 + 0.04 
 
Table 3.5: Binding affinity of photopeptides. 
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Species 
 LpxA 
Acyl Length 
LpxA 
Kd 
 LpxD 
Acyl Length 
LpxD 
Kd 
E. coli  OH-C14  6.21 ± 0.44  OH-C14 0.66 ± 0.03 
A. baumannii  OH-C12 3.01 ± 0.24  OH-C14 8.53 ± 0.31 
C. pneumoniae  Unknown 0.45 ± 0.02  Unknown N/A 
H. pylori  OH-C16 55.4 ± 3.4   OH-C18 N/A 
N. meningitidis  OH-C12 >100  OH-C14 49.9 ± 4.3 
P. gingivalis  OH-C15/16 >100  OH-C17 DNB 
P. aeruginosa  OH-C10 17.8 ± 2.7  OH-C14 >100  
 
Table 3.6: Binding of FITC-RJPXD33 to various LpxA and LpxD. N/A indicates not tested as a 
result of being unable to get the protein soluble at high enough concentration for the binding 
assay.DNB indicates did not bind. The acyl chain lengths incorporated by C. pneumoniae LpxA 
and LpxD are currently unknown. 
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Figure 3.1 Enzymatic activities of LpxA and LxpD in the Raetz pathway. 
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Figure 3.2: Alanine-substitution effects on RJPXD33 binding to LpxA. 
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Figure 3.3: Alanine-substitution effects on RJPXD33 binding to LpxD. 
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Figure 3.4: Alanine-substitution effects on RJPXD33 binding to LpxA and LpxD. 
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Figure 3.5: Direct binding curve of photopeptides to LpxA. 
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Figure 3.6: In-gel fluorescence of photocrosslinked LpxA and LpxD. Photopeptides 1, 3, and 4, 
were all able to crosslink both LpxA and LpxD and exhibit in-gel fluorescence. These 
photopeptides bound in the same location as RJPXD33, as addition of the unlabeled peptide to the 
mixture was able to compete with the photopeptide crosslinking.    
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Figure 3.7 FITC-RJPXD33 titrations of native and iodoacetamide treated LpxD. Fluorescence 
polarization experiments were performed holding FITC-RJPXD33 constant (20 nM) while 
varying concentrations of LpxD. The peptide was able to bind both native and acylated LpxD 
with roughly the same affinity (Kd = 2.8 µM for native LpxD, Kd = 3.1 µM for iodoacetamide 
treated LpxD). 
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Figure 3.8 Structural overlay of LpxA-RJPXD33 onto LpxD-acyl-ACP. The LpxA-RJPXD33 co-
crystal structure monomer (4JO9) (28) is overlaid on the co-crystal structure of LpxD-acyl-ACP 
(4IHF) (29). The 6 C-terminal residues of RJXD33 are in teal, with L6 in close proximity with 
S36 of acyl-ACP. This overlay suggests that the 6 N-terminal residues would further follow the 
proposed acyl-ACP association pocket to LpxA and LpxD, preventing the association of acyl-
ACP to the acyltransferase. 
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Chapter 4
Conclusion & Future Directions
Conclusion 
Phosphopantothenoylcysteine synthetase (PPCS; EC 6.3.2.5; coaB) is a critical 
enzyme in the CoA biosynthetic pathway, as it is responsible for the incorporation of the 
reactive thiol. PPCS performs a two step reaction. In the first step, a nucleotide 
triphosphate is utilized to activate phosphopantothenate by forming a cytidylate 
intermediate. In the second half reaction, cysteine attacks the cytidylate intermediate to 
produce phosphopantothenoylcysteine and CMP. PPCS is broadly divided into three 
types, with Types 1 and 3 existing in bacteria. Type 1 PPCS is found in most bacteria and 
is expressed as a bifunctional enzyme with PPCDC and solely utilizes CTP. Type 3 PPCS 
is a monofunctional enzyme that utilizes solely ATP and has recently been discovered in 
high priority pathogens, including Streptococcus, Enterococcus, and Bacillus.  
Prior to the work of this thesis, the active site of E. coli Type 1 PPCS had been 
characterized and residues N210 and K289 were determined to be catalytic (1,2). K289 
mediates the first half activation of phosphopantetheine and N210 mediates the second 
half cysteine condensation. A co-crystal structure of the cytidylate mimetic inhibitory 
compound JDP03 bound to E. coli PPCS was previously solved by Patrone et. al. (3) but 
no structural data for the bacterial Type 3 PPCS existed. 
This work represents the first molecular characterization of Type 3 PPCS. 
Through a novel multiple sequence alignment of strictly Type 1 and Type 3 PPCS, we 
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were able to identify residues conserved completely across bacterial PPCS. To explore 
Type 3 PPCS in a structural sense, a novel multiple sequence alignment between just 
bacterial PPCS was generated in order to determine completely conserved residues. 
These completely conserved residues were probed through mutagenic studies in order to 
determine their roles in the Type 3 enzyme. 
 In order to evaluate the activity of PPCS in vivo, we developed a double knockout 
model systems. This knockout strain capitalizes on the pantetheine shunt salvage pathway 
present in E. coli, which allows for genetic knockout of the coaBC (dfp) gene cluster to 
be rescued by environmental pantetheine. We showed that this system can be 
complemented with plasmid-based coaB (PPCS) and coaC (PPCDC), from different 
organisms and grow at a rate on par with that of wild-type E. coli. Additionally, this 
system can be used to validate that potential antimicrobials are in fact targeting PPCS, as 
the introduction of environmental pantetheine should recover the grow inhibition. 
 Through saturation mutagenesis of completely conserved PPCS residues, we were 
able to identify N22, D93, and K123 as those with stringent residue requirements. 
Follow-up in vitro characterization using activity assays to determine the binding affinity 
of the mutants to each substrate, we were able to identify that N22 and K123 share 
similar catalytic roles in Type 3 S. pneumoniae PPCS to those of N210 and K289 in Type 
1 E. coli PPCS. Additionally, we determined D93 to be responsible for the required 
divalent cation of S. pneumoniae PPCS. 
 This thesis work also incorporated the characterization of the peptide probe 
RJPXD33. RJPXD33 is a 12-mer peptide able to bind and inhibit both LpxA and LpxD 
of the Raetz Lipid A biosynthetic pathway. The essential nature of lipid A in gram 
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negative bacteria, and the ability of RJPXD33 to target multiple enzymes in the pathway 
make it an ideal candidate as a starting point for the development of small  molecule 
antimicrobials. To do so, we first needed to fundamentally understand the molecular 
binding mechanism of the peptide to both LpxA and LpxD. 
 RJPXD33 was characterized through direct and indirect fluorescence polarization 
binding assays, by synthesizing series of truncated and alanine-mutated peptides. From 
this work, we were able to identify the essential YML motif for the binding of the peptide 
to both LpxA and LpxD. Additionally, we identified Trp9 as integral to the inhibition of 
LpxA and LpxD, and that Lys8 and Asp10 were overall unimportant in the overall 
binding of the peptide. We also were able to test the utility of RJPXD33 as a broad 
spectrum chemical biological probe by testing the ability of the peptide to bind an array 
of bacterial acyltransferases. This research was essential in order to begin the rational 
design of small molecules to target both LpxA and LpxD.   
 TNLYMLPKW was identified as the optimal peptide for high affinity binding and 
inhibition of both acyltransferases, with a sub 6 μM binding affinity to both LpxA (5.7 
μM) and LpxD (0.5 μM), and inhibit LpxA with an IC50 of 26.7 μM and LpxD with an 
IC50 of 2.4 μM. Alanine substitution elucidated that K8 resulted in a slight improvement 
of inhibition of the full length peptide to LpxA (20.6 μM IC50). As a basic residue at this 
position appears to be of little inhibitory or biding consequence to either acyltransferase, 
TNLYMLPAW would be the best peptidic scaffold to begin rational design of small 
molecule dual targeting inhibitors. 
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